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ABSTRACT
Asthma is a complex syndrome which has a significant inflammatory basis 
which results from the complex interactions between heterogenous genetic and 
environmental factors. Although the environmental allergens are fairly well 
known, little information concerning the genetic differences between atopic and 
non-atopic individuals is available. Alpha-1 antitrypsin is the archetypal member of 
the serine proteinase inhibitor or serpin superfamily and the most important 
proteinase inhibitor in the lung with specificity to neutrophil elastase. Genetic 
deficiency of the protein is classically associated with early onset emphysema, 
bronchiecstasis, panniculitis, rheumatoid arthritis and glomerulonephritis. The 
S(E264V), Z(E342K), Ml (213 Ala) and M2 (R101H) variants of alpha-1 
antitrypsin have been implicated in the pathogenesis of asthma. A novel finding 
was the identification of 2 new variants, the M 1E(JOhannesburg) and the 
M IN(johannesburg) associated with asthma in individuals from South Africa. The 
novel polymorphism that we describe in exon II (471) CTG to TTG was found in 
the heterozygous state with the common normal M3 base allele in an individual 
with asthma from the United Kingdom. The superfamily of serine proteinase 
inhibitors control many biological pathways by irreversibly inhibiting their cognate 
proteinases. The recent crystal structure of apantitrypsin bound to trypsin showed 
that inhibition of the proteinase resulted from ester bond formation and 
translocation of the enzyme from the upper to the lower pole of the molecule. The 
complex was also stabilised by interactions between Lys328 and Asn314 of a.p 
antitrypsin and the enzyme. We have shown that mutating these two residues to 
alanines (314Asn—»Ala, 328Lys—»Ala and 314Asn/328Lys ->Ala) resulted in a 
29-fold increase in the dissociation rate constant of the complex. This effect was 
not specific to trypsin but was also seen following complex formation with human 
neutrophil elastase. The crystal structures of reactive loop cleaved a r  
antichymotrypsin, antithrombin, plasminogen activator inhibitor-1 and horse 
leucocyte elastase inhibitor demonstrate that residues that are equivalent to position 
328 or 314 in apantitrypsin are available to form hydrogen bonds with the 
proteinase. Taken together these data identify additional interactions at the serpin- 
proteinase interface that are important in stabilising the inhibitory complex. 
Moreover they demonstrate that the proteinase must be positioned at the lower pole 
of a .1 -antitrypsin in the final complex and not trapped with partial loop insertion.
Knowledge of the molecular basis of variants and polymorphisms, both 
normal and pathogenic, can be useful for the identification of the residues most 
important for protein function
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
1.1 THE SERPIN SUPERFAMILY OF PROTEINS
The existence of proteinase inhibitor activity in human plasma was apparently first 
noted by Fermi and Pernossi in 1894. Since that time a host of investigations have 
been made to determine the various inhibitory activities in this tissue derivative, 
primarily by adding a larger number of proteinases of varying specificities and 
catalytic mechanisms to plasma and plasma fractions (Travis&Salvesen, 1983). These 
experiments were performed to determine the number, type, concentrations, and 
mechanism of action of the various inhibitors, and with the hope of understanding 
their role in the control of proteolytic events within the body (Travis&Salversen, 
1983).
In 1980 Hunt and Dayhoff noted a similarity between the primary structures of 
ovalbumin, alpha-1 proteinase inhibitor (ai-PI) and human antithrombin and proposed 
the existence of a new superfamily of proteins (Table 1.1). Other proteins belonging 
to this superfamily (rat angiotensinogen and mouse contrapsin) were soon identified, 
again based on primary structure similarity (Dolittle, 1983; Hill et al. , 1984). In 1985 
Carrell and Travis coined the term serpin (an acronym for serine proteinase inhibitor) 
as a name for these proteins that described the properties of most members o f this 
superfamily as inhibitors of serine proteinases (Carrell&Travis, 1985).
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Table 1.1: Plasma Serpins
Inhibitor pM/L Mass (kDa) Target
Antithrombin 2 61 Thrombin, factor Xa
Heparin cofactor II 1 66 Thrombin
Antiplasmin 1 70 Plasmin
Plasminogen activator inhibitor io -4 50 Plasminogen activator
Protein C inhibitor 10'2 57 Protein C
Antitrypsin 25 52 Neutrophil elastase
Antichymotrypsin 7 58 Cathepsin G
Cl-inhibitor 2 104 C ls, kallikrein
Angiotensinogen IO'2 50 Noninhibitor
Thyroxine Binding Globulin (TBG) 0.2 54 Noninhibitor
Cortisol Binding Globulin (CBG) 0.6 53 Noninhibitor
The proteinases released by inflammatory cells act on substrates in the extracellular 
space. These proteinases can be divided into four main groups: the serine, cysteine, 
aspartic and metallo-proteinases (Whicher&Evans, 1992). This division is based on 
the nature of the key catalytic group at the active centre. The choice of serpin as a 
name for the family has, however, become increasingly inappropriate and confusing as 
more examples of biologically important, but non-inhibitory, serpins (Zou etal., 1994; 
Steele et al. , 1993) and even serpins that inhibit cysteine proteinases (Ray et al.. 1992) 
have been identified. The name is, however, almost certainly here to stay.
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1.1.1 Characteristic Properties of Serpins
There are three principal properties that set serpins apart from other families of protein 
inhibitors of serine proteinases: (1) Serpins undergo a major conformational change as 
a necessary part of their mechanism of inhibition of proteinases; (2) They are a family 
of metastably folded proteins; and (3) Serpin-proteinase complexes are covalent and in 
almost all cases are effectively irreversible (Gettins et al., 1996).
Serpins require a dramatic partial insertion of the reactive centre as an extra band in 
one of the three P-sheets of the protein for the inhibitory mechanism to operate 
effectively (Gettins et al., 1993). Also, in contrast to almost all other proteins, serpins 
fold in a native conformation that is metastable. This appears to be linked to the need 
for subsequent conformational change during proteinase inhibition (Gettins et al., 
1996).
1.1.2 Occurrence of Serpins
Two of the first serpins identified, anti thrombin and a i PI, are part of a larger group of 
human serpins that together represent about 10% of the total protein in plasma. These 
plasma serpins appear mostly to be involved in regulation of such crucial 
physiological processes as coagulation, fibrinolysis, inflammation, and the immune 
response, with consequent pathology in deficiency states (Gettins et al., 1996). 
Serpins have been identified in many other mammals, amphibians, parasites, insects, 
plants and even viruses (Table 1.2).
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Table 1.2: Species distribution of serpins
SPECIES SERPIN
Human a i -Antichymotrypsin
a|-Antiplasmin
ai-Proteinase inhibitor
Angiotensinogen
Antithrombin
Cl-inhibitor
Corticosteroid binding globulin 
Heparin cofactor II 
Protease nexinl 
Protein C inhibitor 
Squamous cell carcinoma antigen 
Thyroxine binding globulin
Other Mammals ai-Proteinase inhibitor (baboon, dog, donkey, guinea pig, 
monkey, pig, rabbit, rat, sheep) 
a  i-Antichymotrypsin (cow, goat, pig)
Angiotensinogen (cow, mouse, rat, rabbit, sheep) 
Antithrombin (cow, mouse, pig, rabbit, sheep)
Cl-inhibitor (guinea pig, rat)
Collagen binding protein (mouse, rat)
Kallistatin (rat)
Leukocyte elastase inhibitor (horse, pig)
Fish ai-Proteinase inhibitor (carp)
Amphibians Ep-45 (Xenopus laevis)
Birds Antithrombin (chicken)
Collagen binding protein (chicken) 
Ovalbumin (chicken, quail)
Arthropods a i-Antichymotrypsin (Bombyx mori) 
Ala-serpin (Manduca sexto)
Nematodes Unidentified function (Schistosoma heamotobin, 
S.mansoni, Brugia Malayi)
Plants Barley Z protein 
Chymotrypsin inhibitor (wheat) 
Z4 (barley)
Z 7 (barley)
Fungi Corticosteroid binding globulin (yeast)
Viruses CrmA
SPI-3 (vaccinia virus) 
SERP1 (myxoma virus)
Bacteria None known
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1.1.3 Size and Composition of Serpins
Although serpins show some variation in size (figure 1.1), they all contain a core 
domain o f about 360 amino acids that represents the region of high primary and 
tertiary structural homology. This domain contributes about 40kDa to the total size. 
The remainder of the serpin is made up of N- and/or C-terminal extensions to the 
polypetide o f different lengths, as well as in many cases carbohydrates attached at non- 
conserved sites (Gettins etal., 1996). The degree of glycosylation shows a very large 
range and in the somewhat exceptional case of Cl-inhibitor accounts for as much as 
40% of the total mass. Other post-translational modifications are posphorylation of 
the two serines in ovalbumin (Nisbet et al., 1981) and sulfation of two tyrosines in 
heparin cofactor II (Hortin et al., 1986).
Secreted serpins typically are synthesised as a longer pre-protein containing a 
cleavable hydrophobic N-terminal signal sequence. Some serpins such as 
plasminogen activator inhibitor-2 (PAI-2) exist in both secreted and non-secreted 
forms and may rely on an internal non-cleavable signal sequence, which is a 
characteristic o f the ov-serpin subfamily, for export from the cell (Gettins et al., 1996).
Within the core serpin domain, sequence identity can be as low as 30% (e.g., 
ovalbumin and a i PI) or as high as 92% (e.g., two squamous cell carcinoma antigens 
occurring at the same gene locus), (Schneider et al., 1995). Although some serpins 
contain disulphides, others do not. Those that do contain disulphides usually do not 
show conservation, unless the proteins are highly homologous.
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Huber and Carrell have noted 51 residues that are either absolutely conserved in 20 
serpins or involve at most change of phenylalanine to tyrosine. All of these conserved 
residues are either internal or in niches on the surface.
1.1.4 Gene Structure, Chromosomal Location and Evolution
Based on number, size and phase of exons and introns, at least seven distinct serpin 
gene structures have been shown to exist (figure 1.2). Among these groups of serpins, 
introns occur at both equivalent and unrelated positions. Whereas some of the 
exon/intron boundaries occur at positions corresponding to non-structured parts of the 
serpin polypeptide, others occur within stretches of secondary structure. Woo and 
colleagues have proposed that a hybrid of the intron deletion and intron insertion 
models could account for the relationships between serpins. In this model the 
ancestral gene resembled the ai-antichymotrypsin gene. Gene duplication over 500 
million years ago led to the formation of angiotensinogen, whose protein sequence 
then diverged from that of the precursor ai-antichymotrypsin. More recently (between 
500 and 250 million years ago) a second gene duplication led to the precursors of (a) 
ai-antichymotrypsin and ai-antitrypsin and (b) ovalbumin and antithrombin. In 
humans the genes for ai-antichymotrypsin, ai-PI, protein C inhibitor and CBG, are 
despite different functions localised to the same region of chromosome 14 (14q32.1), 
(Billingsley et al., 1993). They may be expressed co-ordinately during inflammation, 
since the distinct functions of proteinase inhibition and corticosteroid delivery may be 
required in concert (Hammond et al., 1990).
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Figure 1.1 Schematic representation of the primary structures of selected serpins to 
illustrate the size and location of the core serpin domain, and the presence of non- 
conserved post-translational modifications. Glycosylation sites, either demonstrated to 
exist or putative, are indicated by ; above the line for N-linked and below the line for 
0-1 inked; P represents a phosphoserine and S represents a tyrosine sulphate. For Cl- 
inhibitor, the high density of glycosylation sites makes it difficult to accurately 
represent all sites present in the N-terminal. (from Gettins et al., 1996).
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Figure 1.2 Gene organisation of selected serpins to illustrate the seven different 
patterns of exons and introns so-far identified. The horizontal bars represent the exon 
coding regions, down arrows indicate the positions of introns, up arrows indicate the 
start position of the mature protein after processing of any signal (from Gettins et al., 
1996).
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1.2 THREE DIMENSIONAL STRUCTURES OF SERPINS
The first X-ray structure of a serpin was determined in 1984 and was that of reactive 
centre-cleaved and therefore inactive ai-PI (Lobermann et al., 1984). It was a further 
six years before the next serpin structure was published. That was also o f a reactive 
centre-cleaved serpin, but of ovalbumin, a serpin with no known inhibitory properties 
(Wright et al., 1990). This structure was quickly followed by that of uncleaved 
ovalbumin (Stein et al., 1991). After this, new structures appeared much more 
frequently and led to the first structure o f a serpin-protease complex (Huntington et 
al., 2000). Together these structures of cleaved and uncleaved inhibitory and non- 
inhibitory serpins have greatly advanced our understanding not only of serpin structure 
but also o f the physical mechanism of their functioning.
1.2.1 The core serpin domain
Although there are striking differences between serpin structures they are all related to 
the reactive centre loop conformation and its interactions with p-sheets A and C. 
Even more striking, however, is the almost invariant structure of the core serpin 
domain. The core domain covers approximately residues 21 to 389 (using the ai-PI 
numbering) and is composed of three p-sheets and nine a-helices. The P-sheets are 
designated A, B and C, and the aphelices A through I. P-Sheet A involves the most 
residues and is composed of 5 strands of polypeptide, followed by P-sheet B which 
has 6 strands and p-sheet C which has 3 strands (Gettins et al., 1996).
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1.2.2 The reactive centre loop
The state of the reactive centre loop (intact versus cleaved) and its conformational 
state (exposed versus inserted into P-sheet A) together with the associated structural 
changes of P-sheets A and/or C account for most of the significant structural 
differences in the core serpin domains (Gettins et al., 1996).
The realisation that the serpins had a flexible reactive site loop first came from the 
crystal structure of cleaved a,-PI determined by Robert Huber’s group. This structure 
showed the complete insertion of the proximal portion of the cleaved reactive loop 
into the central 4th strand position of the A-sheet (Carrell et al., 1997).
The various structural transformations of the reactive centre loop, both definitely 
known and merely postulated, are shown schematically in figure 1.3.
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Figure 1.3 Schematic representation of the structural transformations that the reactive 
centre loop of serpins can undergo. Only the four main strands of p-sheet A (2, 3, 5 
and 6) together with the reactive centre region and strand 1 of p-sheet C are shown. 
(A) The structure of native ovalbumin with the reactive centre in the a-helical 
conformation. (B) The loop-inserted structure of cleaved ai-PI and other cleaved 
inhibitory serpins. (C) The non-loop inserted structure of cleaved on-inhibitory 
ovalbumin. (D) The loop inserted structure of intact but latent PAI-1. (E) Possible 
partially loop inserted structure of serpin in complex with proteinase, at the tetrahedral 
or acyl-enzyme intermediate state, but prior to release of the cleaved new amino 
terminus (from Gettins et al., 1996).
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1.3 Mechanism of action of serpins as suicide substrate inhibitors
1.3.1 Comparison of serpins with other classes of serine proteinase inhibitors
Serpins represent only one of several classes of protein inhibitors of serine proteinases, 
but one that is distinct from the other classes in a number of important respects.
A) Gross structural and thermodynamic differences
One striking difference between non-serpin serine proteinase inhibitors and serpins, 
which have molecular weights o f45-100 kDa, is that these proteinase inhibitors are all 
comparatively small. A second major difference between serpins and other classes of 
non-serpin serine proteinase inhibitors is in the reversibility of complex formation 
with the target proteinase. Whereas most non-serpin serine proteinase inhibitors form 
reversible complexes with proteinases, those with serpins are considered to be 
irreversible with the possible exception of ai-antiplasmin interacting with trypsin and 
chymotrypsin (Shieh et al., 1989).
It has also been shown that spontaneous dissociation of antithrombin-thrombin 
complexes release only cleaved serpin (Danielsson&Bjork, 1983). Related to this 
apparent irreversibility of most serpin-proteinase complexes is the energy difference 
between the native and cleaved forms of serpins. For non-serpin inhibitors the energy 
difference between the cleaved and native inhibitor is close to zero (Estell, et al., 
1980), and both cleaved and uncleaved forms of the inhibitors are effective in forming
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stable complexes with proteinase and thus acting as proteinase inhibitors. In contrast, 
not only is there a very large energy difference between cleaved and uncleaved serpins, 
but the cleaved forms are incapable of acting as inhibitors (Fish et al., 1979). 
Quantitation of the energy differences between native and cleaved serpins is made 
difficult by the very much greater stability of the cleaved forms, which results in them 
being stable even at 100°C (Gettins et al., 1988).
These marked differences in thermodynamic stability between cleaved and uncleaved 
serpins is a manifestation of the more general difference between serpins and other 
protein proteinase inhibitors, namely that native serpins fold in a kinetically-trapped 
metastable state. Indeed serpins belong to a small group of proteins that fold in a 
native conformation that is a kinetically determined local energy minimum rather than 
a thermodynamically determined global energy minimum (Baker&Agard, 1994). This 
metastability can lead to spontaneous change to a more stable conformation such as in 
the formation of the “latent” form of PAI-1. This metastability plays an essential role 
in the inhibitory mechanism.
B) Structural differences in the reactive centre loop
The binding interaction between non-serpin serine proteinase inhibitors and 
proteinases is well understood from a combination of kinetic and X-ray structural 
studies. Although there are differences in the precise position o f the contact 
interaction between inhibitor and proteinase, the very high affinity of the complex 
results in all cases from multiple non-covalent interactions.
13
Most commonly these involve complementarity between residues in the P3-P3' region 
interacting with the S3-S3' subsites on the proteinase (Gettins et al., 1996). In these 
instances the portion of the inhibitor reactive centre that interacts with the proteinase 
adopts an extended (3 conformation that has been termed the “canonical conformation” 
(Bode et al., 1987).
For some inhibitors, such as chymotrypsin inhibitor-2, there are high temperature 
factors associated with the reactive centre loop regions, reflecting some mobility that 
might be beneficial for adapting to the active site structures of different enzymes, with 
consequently lowered affinity for proteinase. However, even in these cases, the 
change in structure of the reactive centre loop itself upon complexation is minor 
(Hubbard et al., 1991). These structurally different classes of serine proteinase 
inhibitor thus present a common conformation of reactive centre loop residues to the 
proteinase that could be said to represent an optimised substrate binding conformation. 
Ironically analysis of actual substrate cleavage sites by trypsin in a number of proteins 
has shown that the conformation at, and surrounding, the cleavage site is far from this 
optimal conformation, thus requiring considerable change in local conformation and 
large changes in loop position relative to the remainder of the structure to interact with 
the proteinase active site (Hubbard et al., 1991).
On the basis of this comparison the (non-serpin) inhibitor-proteinase interaction has 
been described as the classic “lock and key” fit of Fischer, whereas true substrate- 
proteinase interactions are better described as “induced fits.” Such flexibility in 
substrates but not in inhibitors is required to permit adoption of a conformation in
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which the transition state rather than the ground state is stabilised and thus to promote 
the proteolytic reaction rather than inhibition. For the rigid reactive site loop of the 
inhibitors only ground state stabilisation is favoured, with consequent inhibition 
(Gettins et al., 1996).
C) Importance of reactive centre residues in determining specificity
Both serpin and non-serpin serine proteinase inhibitors usually show primary 
proteinase specificity determined by the PI residue. A consequence o f this is that 
changes at this position, whether through species variation, natural mutation or in vitro 
site directed mutagenesis, can result in loss of inhibitory properties or a change in 
inhibitory specificity. An example of this is the methionine to arginine change in the 
serpin ai-PI (Pittsburgh variant), which converts the serpin from an inhibitor of 
elastase to an inhibitor of proteinases involved in blood coagulation (Owen et al., 
1983; Scott et al., 1986; Wachfogel et al., 1994).
In the non-serpin inhibitors, change of PI from lysine or arginine to phenylalanine or 
tryptophan resulted in change from a good inhibitor of trypsin to a good inhibitor of 
chymotrypsin (Jering&Tschesche, 1976). In addition to the role of PI in both types of 
inhibitor, interactions beyond this are also important for effective inhibition. In the 
case of non-serpin inhibitors there is an extended region that can involve residues on 
either side o f the PI residue, from as far away as P6 to P3' (Read&James, 1986). In 
serpins it has also been shown that changes beyond PI can change the proteinase 
specificity (Hopkins et al., 1995; Olson et al., 1995). However, whereas other
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mutations have additive effects in non-serpin inhibitors (Wells, 1990), this appears not 
to be the case for serpins (Hopkins et al., 1995).
D) Inhibitory mechanism of non-serpin inhibitors
For non-serpin inhibitors the portion of the inhibitor reactive centre loop that interacts 
with the proteinase adopts an extended (3-conformation. The extent of interaction is 
variable, but always results from multiple contacts, involving residues on both sides of 
the PI primary specificity-determining residue. Complementarity involves both the 
side chains and the peptide backbone and is usually between the P6-P3 ' region of the 
inhibitor and the S6-S3' subsites of the proteinase. There is little alteration in 
conformation necessary to bind optimally to the target proteinase, resulting in little or 
no loss of binding energy to modify the conformation. The interaction is thus a good 
example of a lock-and key fit and thus resembles a Michaelis complex (Gettins et al., 
1996). The stabilisation of the ground state relative to the transition state ensures that 
a substrate cleavage reaction is not favoured, with the resultant inhibition of the 
interaction. In contrast, good substrates of the same proteinase are more flexible and 
are better described as induced fits. Flexibility in substrates is required to permit 
adoption of a conformation in which the transition state is stabilised rather than the 
ground state, with resulting promotion of the proteolytic reaction. Due to the non- 
covalent Michaelis-like nature of these non-serpin proteinase complexes, they are 
readily reversible unlike the serpins that almost always give irreversible complex 
formation (Gettins et al., 1996).
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1.3.2 Serpin reactions with cysteine proteinases
There are now a number of well-documented instances of inhibition of cysteine 
proteinases by serpins (Ray et al., 1992; Hook et al., 1993; Takeda et al., 1995). 
While there is still a shortage of firm structural evidence for the operation of the same 
mechanism of inhibition of cysteine proteinases by serpins (as compared to that 
available for serine proteinase inhibition), it seems that the same mechanism could 
accommodate all the conditions necessary for effective inhibition of cysteine 
proteinases (Gettins et al., 1996).
According to Gettins et al., (1996), “the most critical attributes for serpins to function 
as inhibitors rather than as substrates are: (a) the ability to loop insert to give more 
stable structures, and (b) the ability to change conformation in the reactive centre loop 
in response to covalent intermediate formation.” Given the similarities in their 
mechanism of substrate cleavage which involves nucleophilic attack on the peptide 
carbonyl to form an acyl enzyme intermediate in both cases, it would seem that serpins 
should, in principle be capable of inhibiting both cysteine and serine proteinases 
(Gettins et al., 1996).
1.3.3 The serpin mechanism: advantages and disadvantages
At the level of protein biosynthesis and folding, the serpins possess the unusual ability 
to undergo facile conformational interconversion and also display features that are 
needed to direct metastable folding. The ability of serpins to fold into a metastable
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state, and to subsequently undergo insertion of the reactive loop into p-sheet A, in an 
essential part of the proteinase inhibition mechanism and is probably one reason that 
serpins are so much larger than other proteinase inhibitors (Gettins et al., 1996).
A means o f regulating the activity of serpins that may have either positive or negative 
consequences is proteolytic inactivation by cleavage in the reactive centre loop by a 
non-target proteinase. Thus human neutrophil elastase, in the presence of heparin, is 
an effective inactivator of antithrombin (Jordan et al., 1987; Jordan et al., 1989), 
through cleavage at the P4-P3 bond (Carrell et al., 1985). Of potential benefit in 
regulation of tissue remodelling and vascularisation, ai-PI can be inactivated by 
matrix metalloproteinases such as matrilysin (Sire et al., 1994).
A major disadvantage of the serpin mechanism results from the very conformational 
lability that enables serpins to function as inhibitors. The need to fold as a metastable 
state and the subsequent ability to undergo loop-to-sheet transitions makes serpins 
sensitive to mutations that affect one or both of these processes. One of the most 
dramatic examples of such a variant is the Z variant of ap P I which, as a result of 
problems during folding (Yu et al., 1995), undergoes polymerisation into sheets of 
linked ai-PI molecules, which are accordingly not secreted into the circulation and 
instead build up inside hepatocytes (Lomas et a l, 1992). It has been conclusively 
shown that polymers of a r PI form by insertion of the reactive loop of one molecule 
into P-sheet A of the next (Sivasothy et al., 2000).
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1.4 Serpin biosynthesis, clearance and receptors
1.4.1 Serpin biosynthesis
As is found with many plasma proteins, the liver is likely to be the major site of 
biosynthesis of circulating serpin. However, may extrahepatic tissues produce serpins 
presumably for the regulation of localised proteolytic pathways. ai-PI is a major 
plasma protein, but is also produced in a number of extrahepatic locations, for 
example by monocytes, neutrophils (du Bois etal., 1991), cornea, kidney and intestine 
(Kelsey et al., 1987; Molmenti et al., 1993). The finding that the gene is under the 
control o f tissue specific promoters (Perlino et al., 1987) and transcriptional initiation 
sites (Hafeez et al., 1992) suggests that there are important regulatory mechanisms that 
needs to be elucidated.
The endoplasmic reticulum (ER) transmembrane protein calnexin, which is a type of 
molecular chaperone, has been shown to associate transiently with newly expressed 
ai-PI and ai-antichymotrypsin in the ER of HepG2 cells (Ou et al., 1993). Calnexin 
appears to bind to incompletely folded glycoproteins and involved in the regulated 
release of these proteins from the ER. Both a]-PI and ai-antichymotrypsin are acute 
phase reactants. In response to an inflammatory stimulus or infection the plasma 
concentrations can increase up to 4-fold (Koj&Regeoczi, 1978; Sehgal et al., 1989). 
The main site o f antithrombin biosynthesis is the liver (Owens&Miller, 1980; 
Fair&Bahnak, 1984) but biosynthesis can also occur in the kidney and endothelial 
cells (Chan&Chan, 1981; Lee et al., 1979).
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Protease nexin 1, which is important in regulating proteolytic pathways in the brain, is 
produced by both astrocytes and glial cells (Guenther etal., 1985; Vaughan, 1993). In 
the case of glial cells, synthesis is increased by cytokines such as interleukin-1 , tumour 
necrosis factor-a and transforming growth factor-p. Protease nexin 1 is also produced 
by HepG2 cells (Kazama et al., 1993) and fibroblasts (Farrell et al., 1988).
1.4.2 Serpin-proteinase complexes clearance
In humans the half-life for serpin-proteinase complexes in the circulation is very much 
shorter than for native serpins, with the serpin-proteinase complex being only a few 
hours compared with over 24 hours for the native serpins. Studies on the clearance of 
radiolabelled (I ) human serpins injected into experimental animals showed that 
there was about a 1 0-fold faster clearance of serpin-proteinase complex than of native 
serpins (Gettins et al., 1996).
In addition, competition studies which examined clearance of several serpin-proteinase 
pairs, including thrombin-antithrombin complex; apantichymotrypsin-cathepsin G 
complex and a  j-proteinase inhibitor-trypsin complex, showed that a common receptor 
appeared to be involved. In the case of a 2-antiplasmin-plasmin complexes, binding 
may involve a separate receptor indicating the possibility of two serpin-proteinase 
complex receptors. The clearance of many serpin-proteinase complexes by the same 
receptor, and the specific recognition o f complexes over native or even cleaved serpin 
indicates that the determinates for rapid removal are associated with the whole 
complex instead of then just the serpin moiety (Gettins et al., 1996).
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1.4.3 SEC Receptor
It has been proposed that there is an abundant, high-affinity cell surface receptor on 
human hepatoma cells and human mononuclear phagocytes that recognise a 
conformation-specific domain of the apPI-elastase complex as well as of the other 
serpin-enzyme complexes and has been called the serpin-enzyme complex (SEC), 
(Gettins et al., 1996). Binding to this SEC receptor activates a signal transduction 
pathway for increased expression of the ap P I gene. In addition, to its role in signal 
transduction the SEC receptor participates in internalisation and delivery of the ai-PI- 
protease complex to lysosome for endocytosis and degradation. Various data indicate 
that this receptor can be found on monocytes, hepatocytes, neural and other tissue. At 
present there is not sufficient evidence to suggest that the SEC receptor could be 
generalised to control the activity of the other serpins other than ap P I (Gettins et al., 
1996).
1.5 Serpins and disease
1.5.1 Alpha-1 Proteinase Inhibitor deficiency (aiPI)
The gene for aiPI has been known to play a role in the pathogenesis of chronic 
obstructive lung disease (which includes asthma) and may result from a disturbed 
balance between extracellular matrix (ECM) proteases and their inhibitors (Walls, 
1995), resulting in the destruction of alveolar walls (Cox, 1995). Studies have 
provided evidence for the involvement of this important proteinase inhibitor in
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bronchial asthma (Gaillard et al., 1994; Cox, 1995). There are two main alleles 
associated with aiPI deficiency, denoted Z and S. A study of 151 children with severe 
asthma found similar frequencies of the Z allele in the asthma group compared to the 
control group. However, the children with steroid-dependent asthma contained more 
Z heterozygotes than the nonsteroid-dependent asthmatics and normal control subjects. 
This suggests a link between the Z allele and asthma severity (Sandford et al., 1996). 
There have been other reports concerning asthma and the aiPI gene. One o f the most 
common alleles at the oqPI (locus) is known as M2 and one report has identified an 
increased prevalence of M2 in asthmatics (Gaillard et al., 1992). The association of 
bronchial hyper-responsiveness and S heterozygosity has been detected in a group of 
asthmatic families (Townley et al., 1990). In addition, there have been reports of an 
association between asthma and another antiprotease deficiency; that is low levels of 
ai-antichymotrypsin. However, the genetic mechanisms have not yet been elucidated 
(Sandford et al., 1996).
1.5.2 The role of PAI-1 in vascular disease
PAI-1 deficiency is somewhat rare but seems to be associated with bleeding episodes, 
particularly after trauma or surgery (Schleef et al, 1989, Dieval et al., 1991; Fay et al., 
1992). More problematic seems the case of an excess of PAI-1. The findings that the 
plasma concentration of PAI-1 is only 0.4 nM and that expression of the gene is 
subject to extensive regulation indicates how detrimental high levels of PAI-1 can be. 
Elevated PAI-1 has been suggested to be a risk factor for myocardial infarction 
(Hamsten et al., 1985; Hamsten et al., 1987).
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1.5.3 Serpins and Alzheimer’s disease
There is a growing body of evidence that proteolytic pathways are essential for neural 
processes such as synaptic plasticity and long term potentiation (Festoff, 1990; Qian et 
al., 1993; Sappino et al., 1993). Also, serpins have been implicated in neurological 
diseases such as Alzheimer’s disease. PAI-2, C 1 -inhibitor and antithrombin have been 
found in amyloid plaques (Kalaria et al., 1993). The most important serpin, however, 
is likely to be apantichymotrypsin. This serpin is found in the amyloid plaques and is 
expressed by astrocytes from Alzheimer’s disease brain (Pasternack et al., 1989), 
Although serum ai-antichymotrypsin does not seem to be a reliable diagnostic marker 
for Alzheimer’s disease ((Hinds et al., 1994). apAntichymotrypsin can modulate the 
ability o f the amyloid P-peptide to form filaments (Ma et al., 1994; Eriksson et al., 
1995).
1.5.4 Serpins and cancer
Two serpins implicated in cancer are maspin and squamous cell carcinoma antigen. 
The acidic variant of squamous cell carcinoma antigen (SCCA2) is expressed 
primarily by malignant cells and is the major form in the plasma o f cancer patients 
(Gettins et al., 1996). It is also possible that rearrangements of the serpin gene cluster 
at 14q32.1 are involved in some types of cancer (Byth et al., 1994).
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1.6 The genetics of atopy and asthma
Studies o f monozygotic and dizygotic twins raised apart show that genetic factors are 
important in the aetiology of atopic asthma and other allergic diseases. There is little 
doubt that there is a major hereditary contribution to the aetiology o f asthma and 
allergic diseases. However, the inheritance of asthma and allergy does not follow 
classical Mendelian patterns that are characteristic of single-gene disorders (Cookson, 
1994; Sandford et al., 1996). The inheritance pattern of asthma demonstrates that it is 
a “complex genetic disorder”. A similar complex inheritance is seen in disorders such 
as hypertension, atherosclerosis, diabetes mellitus and arthritis. All of these diseases 
show a clear hereditary pattern, but the mode of inheritance cannot be simply 
classified as autosomal dominant, recessive, or sex-linked (Sandford et al., 1996). 
Another important feature that distinguishes these complex genetic disorders from 
single-gene disorders is their prevalence. Atopy in the Western world has a 
prevalence of 40-50% (Daniels et al., 1996), with asthma occurring in 4-8% of the 
population, and allergic rhinitis reported in 25% of some populations, as compared to 
the most frequent Mendelian disorder affecting the lungs, cystic fibrosis (CF), which 
occurs once in every 2 000 live Caucasian births, which is approximately 100 times 
less frequent than asthma (Sandford et al., 1996).
Possible reasons that these conditions are not inherited in a simple Mendelian fashion 
include the following: (a) there may be a number of genes that predispose people to 
develop these complex traits - either more than one gene in the same individual 
(polygenic inheritance) or different combinations of genes in different individuals
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(genetic heterogeneity); and (b) environmental factors may be necessary for expression 
of the disease phenotype (Sandford et ah, 1996).
Asthma is characterised by chronic inflammation, with infiltration of eosinophils, 
lymphocytes, and monocytes/macrophages, and is associated with the increased 
expression of several inflammatory proteins, including cytokines, enzymes and 
adhesion molecules in the airways (Hart et al., 1998). Figure 1.4 illustrates the 
functional roles of the various candidate genes that have been implicated in the 
pathogenesis of allergy and asthma.
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Figure 1.4 Functional roles of various candidate genes that may be involved in the 
pathogenesis of atopy and asthma. The candidate genes are shown in the boxes: (1) 
specific MHC/HLA class II antigens allow specific inhaled allergens to be presented 
more effectively to T lymphocytes by monocytes and other antigen presenting cells. 
(2) Specific T cell receptor (TCR) types allow more effective T cell responses to 
particular combinations of MHC/HLA II antigen-allergen complexes. (3) More active, 
or increased production of IL-4 results in enhanced IgE synthesis. (4) Enhanced 
binding and signalling by high affinity IgE receptors on mast cells, basophils and other 
effector cells cause an exaggerated response to allergen-IgE complexes, causing the 
release of more inflammatory mediators and more IL-4, which in turn further boosts 
IgE levels by a positive feedback loop. (5) The allergic inflammatory response to 
mediators and cytokines is increased because of the decreased antiproteolytic activity 
of alpha-1-protease inhibitor (aiPI) and other anti proteases, and/or because of a 
disruption of the protease-antiprotease balance. (6) The smooth muscle response to 
contractile agonists released from effector cells is enhanced due to defective or 
downregulated p2-adrenergic receptors (from Sandford et al., 1996).
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Linkage to chromosome 14q and the T Cell Antigen Receptor (TCR)
Linkage has been demonstrated between the a region of the TCR locus and specific 
IgE responses (Moffatt et al., 1994). The evidence for linkage was assessed using 312 
sib-pairs. The linkage pattern suggested a recessive genetic effect that was detected in 
two separate population samples. The results of this study showed that a gene or 
genes in the TCR-a region might modify specific IgE responses in atopic individuals 
(Moffatt et al., 1994). The region also contains the 6 chain TCR genes, which are 
found within the a  locus; therefore, they are also candidates for linkage (Sandford et 
al., 1996). Although this result has not been replicated independently, it suggests that 
polymorphisms within the TCR genes may limit an individual’s ability to respond to 
specific antigens (Sandford et al., 1996). Chromosome 14q contains many genes that 
could contribute to the susceptibility of IgE-dependent diseases. These include the 
immunoglobulin heavy chain genes (IGH) with important functions in 
immunoglobulin class switching in B cells, the nuclear factor kappa B inhibitor 
(NfxBI), the transforming growth factor beta 3 (TGF-P) and the transcription factor 
FOS (figure 1.5). Polymorphisms in such genes or other unidentified genes in the 
region may modulate total serum IgE and predisposition to allergic disease (Mansur et 
al., 1999).
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Figure 1.5 Chromosome 14 map showing the cytogenetic regions, the corresponding 
relative position and order of the markers and the candidate genes mapped to this 
chromosome. The (sex-averaged) distance in centimorgans and the order of the 
markers generally correspond to published maps. The relative positions of the 
candidate genes are based on data obtained from the Genetic Location Data Base 
(LDB). Abbrevaitions: MAX=oncogene wryc-associated protein; IF127=interferon- 
alpha inducible factor 27; TCL-l=T-cell lymphoma factor 1; IGHE=immunoglobulin 
heavy chain epsilon locus; IGHV=immunoglobulin heavy chain variable locus (from 
Mansur et al., 1999).
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Nuclear Factor-KB and asthma
Asthma is associated with increased expression of inflammatory proteins. The 
molecular regulatory pathways involved in the induction of chronic cytokine 
expression and the recruitment and activation of inflammatory cells in asthma are not 
well understood, but there is an increasing recognition that these processes involve 
increased transcription of inflammatory genes and that is regulated by transcription 
factors. One such transcription factor, nuclear factor-kB (NF-kB), regulates the 
expression of a wide range of genes involved in immune and inflammatory response 
(Hart et al., 1998).
The observation that some cytokines regulated by NF-kB, such as TNF-a and IL-ip, 
can also activate NF-kB expression, indicates that this may represent a feed-forward 
amplifying loop that could form the basis for the persistence of the chronic 
inflammatory process in asthma. Although NF-kB has thus far been considered as 
mediating acute inflammatory responses, it has been shown to be chronically activated 
in chronic inflammatory conditions such as inflammatory arthritis and atherosclerosis 
(Brand et al., 1996; Marok et al., 1996).
It has been shown that the chronic airway inflammatory process of asthma is 
associated with an increase of activated NF-kB, which may play an important role in 
inflammatory and immune responses. NF-kB is not specific for asthma, but may act in 
synergy with other transcription factors to induce maximal gene expression. The 
specificity o f the inflammatory and cellular responses in asthma may depend on the
29
interaction of NF-kB with other transcription factors (Hart et al., 1998). Further 
studies are needed to characterise the roles of the NF-kB family of transcription factors 
in this interaction in asthma and to determine whether the levels of these transcription 
factors determine the severity and course in disease.
Linkage to Chromosome l lq l3  and the High-Affinity Immunoglobulin E 
Receptor
Chromosome 11 q 13 was implicated in the pathogenesis of atopy during a random 
genome search by Cookson et al. (1989), although further evidence exists for non­
linkage in many large families (Cookson, 1994). The initial study caused much 
controversy over its broad definition of atopy and it’s failure to replicate linkage in 
other populations (Hizawa et al., 1992; Lympany et al., 1992). A sib-pair analysis on 
743 subjects conducted to reassess the evidence for linkage showed robust evidence 
for linkage o f atopy to chromosome 11 q 13. This linkage was independent of the 
definition of atopy and was only observed through the female line (maternal 
inheritance) (Cookson, 1994). A suggested mechanism for this was the influence of 
the maternal immune system on the foetus or neonate (Sandford et al., 1996) or 
imprinting o f the paternal copies of the gene (Hopkin, 1995). Imprinting is a process 
by which a particular gene is differentially activated or silenced (probably by the 
demethylation or methylation of CPG islands on the gene) depending on the sex of the 
parent from whom it was inherited (Razin&Cedar, 1994; Sandford et al., 1996). It 
was suggested that the atopy gene was only expressed when inherited from the mother, 
indicating that immunological interactions between mother and child, rather than
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genomic imprinting, might be responsible for the maternal effect on the inheritance of 
the atopy gene on chromosome 11 q 13 (Daniels et al., 1996).
In subsequent studies, investigators have used a maternal inheritance model for the 
linkage analysis. Shirakawa and colleagues (1996) found linkage to an atopy gene on 
chromosome 11 q l3 in a Japanese population. All these observations support the 
notion that atopic asthma is indeed a polygenic disorder.
The most likely position of the atopy gene was found to coincide with that of the high 
affinity receptor for IgE (FcsRip) (Sandford et al., 1993). Linkage studies of the 
FcsRip locus have generated conflicting results and it has been suggested that FcsRip 
(or another gene nearby) may predispose patients to bronchial hyper-responsiveness, 
rather than to atopy (Van Flerwerden et al., 1995). A variant of the FcsRI receptor 
(Leu 181) was detected that segregated with atopy when maternally inherited, a 
finding which supported the hypothesis that FcsRip was the gene responsible for the 
linkage in 11 ql 3. A possible model for the action of this mutation is that it increases 
the signal transduction activity of the receptor. This change would also increase the 
level of activation of mast cells which release interleukin 4 (IL-4), which would, in 
turn, stimulate the synthesis of higher levels of IgE (Sandford et al., 1996). The study 
by Shirakawa and co-workers (1996), also showed the absence of association between 
atopy and gastric intrinsic factor (GIF) and CD20 (the 5' and 3' flanking genes of 
FcsRip, respectively), further supporting the candidacy of FcsRip as the atopy gene on 
chromosome 11 q 13. Another two studies have also shown positive associations 
between atopy phenotypes and polymorphisms in the 11  q 13 region; one within the
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FcsRip gene (Shirakawa et al. 1995) and one with a marker from the 11 q l3 region 
(Hizawa et al., 1995).
Other candidate genes
There have been studies suggesting that atopy, asthma and bronchial hyper­
responsiveness are associated with heterozygosity for cystic fibrosis (CF) of the 
pancreas (Gerrard, 1985). It was found that heterozygosity for the most common CF 
allele (±F508) might protect against asthma. It was suggested that this heterozygote 
advantage could account for the high prevalence of the allele in the Caucasian 
population, however further studies have not been able to find an association between 
CF and atopic asthma (Sandford et al., 1996).
Similarly, a possible connection between asthma and familial Mediterranean fever 
(FMF) has recently been investigated. The high rate of heterozygosity for the FMF 
gene in some populations suggests that there may be a heterozygote advantage for 
FMF, however the results of this study were inconclusive (Sandford et al., 1996).
A plausible candidate for corticosteroid resistance in asthmatic subjects is the 
glucocorticoid receptor gene. A missense mutation in this gene had previously been 
found to be responsible for familial glucocorticoid resistance (Hurley et al., 1991). In 
one study the investigators analysed six corticosteroid-resistant and six corticosteroid- 
responsive asthmatics and compared the data to the wild type gene sequence. As no 
mutations were found in any of the subjects, this suggested that the cause of
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corticosteroid resistance in these asthmatics does not lie in the structure of this gene 
(Sandford et al., 1996).
The results o f a recent study have provided evidence that the gene for interferon-y 
(INF-y) may be involved in the production of the atopic state. INF-y is a good 
candidate gene for atopy, since it acts as an antagonist to IL-4 and downregulates the 
production of IgE from B cells (Tang et al., 1994). The authors found that low cord 
blood INF-y levels were predictive of atopic symptoms at age 12 months, suggesting 
that reduction of INF-y secretion is a cause rather than a result of the atopic state 
(Tang, et al, 1994).
There are complete genome searches underway that systematically attempt to discover 
all the genes involved in susceptibility to atopy and asthma. The results of these 
searches will identify additional candidate genes from those known to be part of the 
allergic pathway. It is also likely that previously unknown genes will be identified. 
This search should lead to considerable advances in our knowledge of the mechanisms 
that lead to asthma and other allergic diseases (Sandford et al., 1996).
1.7 Mechanisms of airway inflammation in asthma
Until recently, asthma has been viewed primarily as a respiratory disease of acute 
airway obstruction. Thus, research and therapeutic attention focussed principally upon 
mechanisms leading to acute bronchospasm. Consequently, first-line therapy 
consisted of bronchodilators to regulate airway smooth muscle contraction. The
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contribution of other components of airway obstruction, as well as the potential benefit 
o f anti-asthma therapy directed towards control of these abnormalities, has been 
largely neglected. However, the approach and focus in asthma therapy and concepts of 
pathogenesis have begun to change considerably.
There is currently a general consensus that patients with asthma have inflammatory 
changes in the airway wall, with increased numbers of activated mast cells, 
eosinophils, macrophages and T-lymphocytes. In addition, there is commonly 
epithelial shedding. These changes have been observed in bronchial biopsies of even 
the mildest of asthmatic patients and have been observed in patients with asthma of 
different clinical types (Saetta et al., 1992).
It is now becoming clear that cytokines released from inflammatory and structural 
cells in the airway may play a major role in co-ordinating and perpetuating chronic 
inflammation. Identification of the cytokines involved in asthma and their effects on 
cell function are now an important focus for research (figure 1.6). Cytokines produce 
chronic changes in cell responsiveness by influencing the transcription of certain genes 
that may result in the altered expression of receptors, enzymes and regulatory proteins 
(Muegge&Durum, 1990).
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Figure 1.6 Schematic representation of airway hyperreactivity and inflammation in 
asthma, emphasising a parallel rather than sequential interrelationship (from Chapman 
etcil., 1993).
Elucidating the mechanisms that are involved in the development and perpetuation of 
the inflammatory and obstruction of the airways that is characteristic of asthma is 
crucial. The following brief review of the cells participating in allergic airway 
reactions focuses on the cellular and mediator mechanisms that are believed to be 
essential for the asthmatic diathesis.
1.7.1 Mast cells
Mast cells (MCs) are high affinity IgE receptor bearing cells that are present in the 
airway epithelium which appear to be activated in allergic and inflammatory 
responses. Mast cell mediators such as histamine and tryptase are present in 
bronchoalveolar fluid. Mast cells may be activated by an inhaled allergen via an IgE 
dependent mechanism (which involves the cross-linking by allergen, and 
internalisation o f IgE receptors), (Nil sson&Schwartz, 1995). Mast cells possess high- 
affinity receptors that bind IgE. Cross linkage of cell-bound IgE by binding of 
allergen results in a rise in intracellular calcium concentration and activation of protein 
kinase C, leading to phosphorylation of a granule membrane protein. Mast cell 
degranulation releases histamines and tryptase (Marom, 1991). This IgE-mediated 
mechanism initiates arachadonic acid metabolism to generate leukotrienes and 
prostaglandins, which in conjunction with histamine, are undoubtedly involved in the 
bronchospastic response of their airway smooth muscle contractile properties 
(Drazen&Austen, 1981). The MCs generation and release o f chemotactic factors then 
sets the stage for recruitment of other inflammatory cells to the airways, and the 
development of the late asthmatic response (LAR) (figure 1.7).
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Figure 1.7 Mechanisms involved in the development of airway inflammation and 
bronchial hvpereactivity in asthma (from Richards et a!., 1992).
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It has been reported that murine MCs synthesise a variety of cytokines upon IgE 
receptor aggregation and internalisation, and although data on the cytokine production 
by human MCs are limited, it is possible that MCs are pivotal in recruiting and 
priming inflammatory cells in sensitised individuals (Arm&Lee, 1992). In vitro 
studies have demonstrated that several different cytokines are produced by MCs, 
including interleukins (IL)-3,4, 5 and 6 , interferon (INF)-y and tumour necrosis factor 
(TNF)-a (Valent, 1994). Both IL-3 and stem cell factor (SCF), a unique activation 
factor for human MCs, are the major cytokines involved in MC differentiation (Valent, 
1994). Furthermore, emerging data suggest a similar MC cytokine profile in humans 
(Valent, 1994). The ability of MCs to produce such a plethora of cytokines provides 
them with great potential for interactions with other cell types to modulate 
homeostatic, allergic, inflammatory and host defence functions. Furthermore, an 
autocrine role for these cytokines on cell function, growth and differentiation should 
be considered (Nilsson&Schwartz, 1995).
1.7.2 Basophils
Basophils have long been considered the circulating counterpart of MCs. Their exact 
function remained elusive for many years, however, recent studies have shed some 
light on the contribution of basophils to various illnesses. The blood basophil count 
increases during the pollen season, suggesting that basophilopoiesis may be influenced 
by environmental factors, such as allergens (Alam&Grant, 1995).
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The late-phase allergic response (LPR) induced by antigen challenge in highly allergic 
patients seems closely related to the naturally occurring reaction in chronic allergic 
disorders. The number of metachromatic cells increases at the site of LPR.
Since both basophils and mast cells release similar mediators, the exact contribution of 
each cell type proved difficult to determine (Alam&Grant, 1995). However, it was 
discovered that the profile of mast-cell/basophil-derived mediators released in the 
early and late phase allergic reaction is not identical. Histamine is detectable in both 
phases. Prostaglandin D2 (PGD2), a major mediator produced by mast cells, but not by 
basophils, is detectable in the early but not the late phase allergic reaction (Naclerio et 
al., 1985).
Metachromatic granules of basophils contain a large number of pharmacologically 
active mediators that are released upon basophil activation. Mediators are typically 
classified as preformed and newly generated. The preformed mediators are histamine, 
neutrophil chemotactic factor, N-a-p-tosyl-L-arginine methyl ester hydrochloride 
(TAME) esterase and kallikrein, while the leukotrienes LTC4, LTD4 and LTE4 and 
platelet activating factor (PAF), are the most important lipid mediators that are 
generated almost immediately after allergen challenge (Busse et al., 1994; 
Alam&Grant, 1995). It has been well established that viral infection of the airways 
causes exacerbation of asthma. Although the mechanism of such an exacerbation may 
be complex, incubation of basophils with viruses results in enhanced mediator release 
and chemotaxis (Chonmaitree et al., 1991). Thus, the heightened mediator release 
from basophils may exacerbate the symptoms of asthma.
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1.7.3 Eosinophils
O f the effector cells in asthma, the eosinophil has possibly the most important and 
potentially pivotal role in generating airway inflammation. The biology of the 
eosinophil is an indication of this cell’s potential relevance to asthma (Weller, 1991; 
Howell, 1995). In 1975, Horn and co-workers examined the usefulness of total 
eosinophil counts in the diagnosis and management of steroid dependent asthma. 
They found that eosinophil counts in a cohort of asthma patients paralleled disease 
severity. Total eosinophil counts were inversely related to pulmonary function and a 
rising eosinophil count was found to be associated with increasing bronchial 
obstruction as reflected by changes in specific conductance, forced expiratory volume 
in 1 second (FEVi), and maximum mid-expiratory flow rate.
Recent data indicate that eosinophils themselves can elaborate proinflammatory 
cytokines in allergic reactions. Initial studies demonstrated that human eosinophils 
express and release transforming growth factor p (TGF-P) and interleukin-1 (IL-1), 
(DelPozo et al., 1990; Wong et al., 1990). Although the relevance of TGF-P to 
allergic inflammation is unclear, IL-1 has the capacity to induce adhesion-molecule 
expression on endothelial cells and is itself an eosinophil activator. Recent studies 
have suggested that eosinophils have the capacity to synthesise IL-3, GM-CSF and IL- 
5 (Desreumaux et al., 1992; Kita et al., 1991; Moqbel et al., 1991).
Thus, although the T lymphocyte is considered to be a major source of these cytokines, 
it is possible that eosinophils themselves also contribute to the overall cytokine
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production in allergic airway inflammation. This raises the possibility of an autocrine 
mechanism whereby stimulated eosinophils may both release and respond to 
cytokines, such as IL-1, IL-3, IL-5 and GM-CSF. Thus there is the potential for a self- 
perpetuating cycle, with continuous eosinophil infiltration and activation, and 
consequently chronic inflammation (Bjornsdottir et al., 1995).
The recent observations indicating a dependence on the presence o f functional T 
lymphocytes to produce LAR eosinophilic inflammation of the airways, suggest that a 
product derived from T lymphocytes will be the “activation” factor for eosinophils. 
However, further in-depth studies of eosinophil-T-lymphocyte interaction will be 
required (Bjornsdottir et al., 1995).
1.7.4 Neutrophils
The evidence that neutrophils play a critical role in bronchial asthma is controversial. 
Neutrophils appear to be normal resident cells of the larger airway. Similar numbers 
of neutrophils have been found in bronchial wash and in bronchial biopsies in 
asthmatic subjects, in subjects with chronic bronchitis and in control healthy subjects 
(Kirby et al., 1987; Fabbri&Ciaccia, 1992; Saetta et al., 1992). The fact that the 
number o f cells is no different does not exclude the possibility that cells may have a 
different degree of activation. For instance, the plasma chemotactic activity for 
neutrophils is increased and peripheral-blood neutrophils show markers of activation 
during active asthma, after exercise-induced asthma and during early and late 
asthmatic reactions induced by allergens and toluene diisocyanate (TDI) (Sastre et al.,
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1990).
Interestingly, the percentage increase in plasma neutrophil chemotactic activity 
correlates with the percentage decline of FEV i of the early asthmatic reaction (Sastre 
et al., 1990). In humans, bronchoalveolar neutrophilia occurs before the onset and 
during the first few hours of the allergen-induced late asthmatic response and the 
increase of neutrophils is much larger than the increase of the number of airway 
eosinophils, the neutrophil increase usually precedes the eosinophil increase, the 
airway neutrophilia and the increased plasma chemotactic activity and activation of 
circulating cells are all prevented by anti-inflammatory steroids and cromolyn, which 
attenuate spontaneous allergen-precipitated asthma attacks, thereby suggesting as 
association between asthma attacks and the migration and activation of neutrophils in 
airways. Circulating neutrophil-generated superoxide anion (CV) is increased in 
young asthmatics and correlates with the degree of histamine-induced bronchial 
hyperesponsiveness (Fabbri et al., 1995).
Even stronger evidence for the role of neutrophils in asthma comes from several 
studies which have demonstrated that these cells have the ability to synthesise and 
release immunoregulatory cytokines, which include TNF-a, IL-ip, and the IL-1 
receptor antagonist (IL-IRa), IL-8, transforming growth factor (TGF)-(31 and IL-6 , 
although the evidence for the release of the latter is contradictory. All these cytokines 
(excluding IL-lra), as well as granulocyte colony-stimulating factor (G-CSF) and GM- 
CSF significantly prolong neutrophil survival (Cassatella, 1995).
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In addition, the neutrophil is a potential source of a wide variety of mediators, 
including potent lipid mediators such as prostaglandins, thromboxanes, leukotrienes 
B4 and PAF, which may then contribute to airway responses and/or exacerbation of the 
inflammatory response. From lavage studies, it is known that there is a neutrophilia 
present before, during and after late (but not early) asthmatic reactions induced by 
allergens (Metzger et al., 1987).
Although there is substantial evidence that neutrophils may be involved in asthma 
attacks and asthma exacerbations, and although neutrophil products can indeed alter 
airway function, the role of these cells in causing the pathologic and physiologic 
features of asthma remains to be established.
1.7.6 Macrophages and monocytes
Alveolar macrophages (AM) and mononuclear cells express FcERII (CD23). The 
proportion of monocytes and macrophages expressing CD23 is increased in allergic 
patients compared to normal individuals and is further enhanced following airway 
antigen challenge (Borish et al., 1991). Macrophages and monocytes are also 
activated by antigen in an IgE-dependent manner to transcribe and secrete cytokines 
(IL-lp) and TNF-a (Borish et al., 1991), produce superoxide anion, release p- 
glucuronidase and other lysosomal enzymes and augment cytotoxicity 
(Calhoun&Jarjour, 1995).
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Upon activation, AM and mononuclear cells release a plethora of compounds which 
have been implicated in or linked to asthma. These factors can be broadly grouped as: 
(1) chemotactic factors such as LTB4, IL-8, complement fragments and a neutrophil 
chemotactin distinct from IL-8, all of which can serve to recruit granulocytes; (2) 
cytokines and other cell-activating factors which includes IL-1 [3, TNF-a, IL-6 and 
GM-CSF; (3) smooth muscle and mucous gland activators, including LTC4, PGD2 
(smooth muscle spasmogen), endothelins 1 and 3 (regulate smooth muscle tone), LTB4 
and IL-ip (promote dose-dependent mucous glycoprotein secretion); and (4) direct 
inflammogens which include (3-glucuronidase, neutral proteases and several lysosomal 
enzymes, which, as mentioned previously, are released following IgE receptor cross- 
linking, and all of which are believed to be instrumental in amplifying the 
inflammatory response (Arm&Lee, 1992; Calhoun&Jarjour, 1995; Drazen et al., 
1995).
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1.8 Objectives of the present investigation
The striking conservation in the sequences, probable mechanism and structure of 
serpins from organisms as diverse as viruses, barley, insects and mammals clearly 
show how remarkable the serpins are. Studies at both the protein and genetic level 
have much to tell us about the phylogenetic relationships between organisms as well 
as the evolution of different serpins within a particular organism. The advances in 
molecular genetics and the increased understanding of the biochemistry of serpins 
have done much to enhance our understanding of the role of serpins in human disease 
and will continue to do so.
This area is likely to expand both diagnostically and therapeutically, not only for 
serpin-deficient states but also as the role of serpins in the pathogenesis of disease 
caused by viruses and parasites in elucidated. With this in mind the present study was 
undertaken in order to: (a) characterise new variants of ai-proteinase inhibitor in 
association with asthma; and (b) assess the stability of the newly characterised serpin- 
proteinase complex.
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CHAPTER 2
CHARACTERISATION OF NEW VARIANTS AND A NOVEL 
POLYMORPHISM OF ALPHA-1 ANTITRYPSIN
2.1 Introduction
Alpha-1 antitrypsin ( a r AT) deficiency is an autosomal hereditary disorder 
characterised by low serum and lung levels of ai-AT, a high risk for the development 
of emphysema in the 3rd and 4th decades, and a lesser risk for the development of liver 
disease, particularly in childhood (Crystal et al., 1990). This disorder is an 
extraordinary example of the power of modern genetics (Crystal et al., 1990). It was 
first recognised in 1963,Laurell and Eriksson discovered the disease a i AT deficiency 
by noting a marked reduction of the ai-globulin band in approximately 1 of 500 serum 
protein electrophoresis patterns of a random Swedish population.
ai-A T is an inhibitor o f serine protease’s, including neutrophil elastase, trypsin, 
chymotrypsin, cathepsin G, thrombin, tissue kallikrein, factor Xa and plasminogen 
(Carrell et al., 1986; Travis&Salversen, 1983). For this reason, it is sometimes 
referred to by the more general term a|-proteinase inhibitor (aiPI). ai-A T deficiency, 
one of the most common lethal hereditary disorders of Caucasians o f European 
descent, is an autosomal recessive disorder characterised by reduced serum levels of 
aiAT, a 52-kDa glycoprotein that functions as an antiprotease (Crystal et al., 1989;
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Carrell et al., 1982). The deficiency state is caused by mutations in the ai-A T gene, a 
pleomorphic 12.2-kb, 7-exon gene on chromosome 14 at q31-31.2 ((Long et al., 
1984). The major clinical manifestations o f apA T  deficiency relate to the function of 
ai-A T and where it is made. apA T  serves as an inhibitor of neutrophil elastase (NE), 
a powerful, destructive proteolytic enzyme stored in neutrophils. The liver is the 
major site o f apA T  gene expression, releasing 2g of apA T  into the circulation daily. 
ap A T  diffuses into most organs, where it protects extracellular structures from attack 
by NE released by activated or disintegrating neutrophils (Crystal, 1990).
The lower respiratory tract is particularly vulnerable to a deficiency of apA T , which 
normally represents > 90% of the anti-NE protective screen of the alveolar walls 
(Gadek et al., 1981; Wewers et al., 1987). When serum apA T  levels are < 11 pM, 
there is insufficient apA T  to protect the lower respiratory tract from its burden of NE, 
permitting progressive destruction of the alveoli (Crystal, 1990).
2.1.1 Structure of apAT
The ap A T  protein is a single chain of 394 amino acids with three complex 
carbohydrate side chains (figure 2.1). The microheterogeneity of apA T  observed in 
isoelectric focussing (IEF) analysis of serum at pH 4-5 results mostly from differences 
in these carbohydrates. The two parental apA T  genes are codominantly expressed. 
Expression is controlled at the transcriptional level through sequences flanking, and 
within, the three 5' non-coding exons (figure 2.2). Hepatocytes are the major source
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of ai-A T, but the gene is also expressed in mononuclear phagocytes and neutrophils, 
and possibly megakaryocytes, islet cells and intestinal epithelial cells (Crystal, 1989; 
Perlmutter et al., 1989; Mornex et al., 1986).
ai-A T, has been crystallised in its active form (Elliott et al., 1996; Elliott et al., 1998 
and Ryu et al., 1996) and it crystallises after proteolytic cleavage at the reactive site 
(Loebermann et al., 1984). Analysis of the crystal structure indicates that the single 
polypeptide chain is organised into well-defined secondary structural elements: three (3 
sheets and eight a helixes. apA T  contains one cysteine residue, as indicated by both 
protein and DNA analysis. No disulfide bridge is present in the protein, although the 
thiol group can form a disulfide bond with other proteins, such as the IgA heavy chain 
and the thiol group of immunoglobulin k light chain (Cox, 1995).
ai-AT shows considerable genetic variability, having more than 70 genetic variants (PI 
types), many of which have been sequenced. Most variants are associated with 
quantitatively and qualitatively normal apAT. Further variation can be revealed at the 
DNA level where a number of restriction enzymes reveal polymorphisms.
apA T is modified during its passage through the endoplasmic reticulum. Some of this 
modification is reflected in the micro-heterogeneity observed in acid starch gel and 
agarose electrophoresis and in polyacrylamide isoelectric focussing, as is typical for 
glycoproteins near their isoelectric point. Eight bands were originally noted, 
numbered from 1 (anodal) to 8 (cathodal); bands 4 and 6 contain 40 and 35 percent, 
respectively, of the total oq-AT and have isoelectric points of 4.52 and 4.59 (Cox,
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1995). Much of the heterogeneity is due to differences in the type of carbohydrate side 
chain. Three carbohydrate side chains per molecule are attached at asparagine 
residues 46, 83, and 247. The carbohydrate chains may be biantennary or triantennary, 
terminating in two or three N-acetylneuraminic acid residues. The electrophoretic 
mobility of ai-AT is sequentially shifted cathodally by incubation with neuraminidase 
as N-acetylneuraminic acid residues are removed.
The gene coding for ai-AT, 12.2kb in length, includes a 1434-bp coding region. The 
gene contains six introns; exons 1A through 1C, the 5' portion of exons 2, and the 3' 
portion of exon 5 are non-coding regions (figure 2.3). The largest intron (between 
exons 1C and 2) is 5.3kb in length and contains a 143-amino acid open reading frame, 
an Alu sequence, and a pseudo-transcription-initiation region. The open reading frame 
does not appear to be an actual protein-coding region (Cox, 1995).
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Figure 2.1: The normal ai-AT protein shown in its linear form, a 394-amino acid 
single chain with three asparaginyl-1 inked complex carbohydrate side chains at 
residues 46, 83 and 247. During its synthesis, the molecule folds into a spheroid shape 
determined by nine a-helices (A—>1) and three p-pleated sheets made up of parallel 
and antiparallel strands (sheet A, strands 1-6; sheet B, strands 1-6; sheet C, strands 1- 
3). Two internal salt links (Glu342—Lys290; Glu2b4—Lys387) help stabilise the molecule 
and play an important role in the pathogenesis of common deficiency states. The three 
carbohydrate side chains are on the surface of one half of the spheroid while the 
Met358—Ser3s7 inhibitory site that combines with NE is localised at the opposite end 
(from Crystal, 1990).
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Figure 2.2: The normal ctpAT gene spans 12.2 kb and consists of three noncoding 
exons (1 A, IB, 1C) and four coding exons (II-V). Exons IA-Ic are used by a variable 
degree by oq-AT synthesising cells, with most apAT transcripts starting in the middle 
of exon Ic. 5' to exon IA and in the middle of Ic are typical cis-acting consensus 
promoter sequences. In the region between IB are two sequences capable of binding the 
c-jun protein (AP-1). The start codon (ATG) is in exon II followed by sequences 
coding for a 24-residue signal peptide. Sequences for the 394-residue mature protein 
start in exon II (Glu1) and end in exon V at the TAA stop signal. Also identified are 
the locations of sequences coding for the carbohydrate (CHO) attachment sites (Asn 
46, 83, 247), the Met338 at the active inhibitor site, and the mRNA polyadenylation 
signal (from Crystal, 1990).
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Figure 2.3: (A) PI and other loci in the serpin superfamily cluster on chromosome 14, 
as determined by pulsed field gel electrophoresis. PIL = PI-1 ike, CBG =corticosteroid 
binding globulin, PCI = protein C inhibitor, AACT = a r antichymotrypsin. (B) cq-AT 
gene and flanking regions. Coding regions are solid rectangles, introns are open 
rectangles, and untranslated regions are dotted rectangles. Crosshatched regions are 
exons of macrophage DNA. Asterisks indicate site of polymorphisms for the following 
restriction enzymes (those in the square brackets at the right indicate polymorphisms 
in the 3' homologous region): A = Avu II; B = Bam HI; Bg = Bgl II; BS = Bsl Eli; M = 
Msp I; Ma = Mae III; T = Taq I; Rl = Eco Rl; Ss = Sst I; S and Z circled = site of 
mutations in PI*S and PI*Z, respectively. Genomic probes 4.6 and 6.5, are indicated. 
The arrow marks the position of the CA repeat (from Cox, 1995).
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DNA and protein sequencing studies have indicated homology not only between some 
of the protease inhibitors, but also between inhibitors and other plasma proteins, as 
well as with chicken ovalbumin. Human ai-AT and ai-antichymotrypsin share 56% 
homology in their coding nucleotide sequences and 42% homology in their amino 
acids. Human ai-AT and protein C inhibitor share 42% amino acid identity. An 
unexpectedly high degree of homology has been observed between ai-AT and two 
non-inhibitor human plasma proteins: thyroxine-binding globulin, located on the X 
chromosome (58%) (Flink et al, 1986) and corticosteroid-binding globulin, located on 
chromosome 14 (53%) (Underhillc&Hammond, 1989). There is 28% homology 
between the amino acid sequences of antithrombin III and apA T (Kurachi et al., 
1981), and 27% homology between Cl inhibitor and ai-AT (Tosi et al., 1986); the 
position and number of introns is very different however, probably indicating a 
relatively ancient divergence from a common ancestral gene several hundred million 
years ago.
2.1.2 Physiology of ai-AT
Alpha-1 antitrypsin inhibits a broad spectrum of serine proteases. Because of its 
efficiency of inhibition, broad substrate specificity and ready access to tissues, apA T 
plays an important role in defending tissues from proteolysis. apA T inhibits most 
serine proteases tested to date, including pancreatic and neutrophil elastase, neutrophil 
cathepsin G, pancreatic trypsin and chymotrypsin, collagenase from skin and synovia, 
acrosin, kallikrein, urokinase and renin (Cox, 1995). Since apA T increases during the 
acute-phase response and is also a trypsin inhibitor, and since trypsin inhibitors are
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known to have antibacterial activity, ai-AT may play some role in resistance to 
infection. The association of ai-AT deficiency with a spectrum of inflammatory 
diseases suggests that ai-AT is important in the inflammatory response.
The two major sites of apA T gene expression are hepatocytes and the mononuclear 
phagocyte family of cells (Permutter et al., 1985). On average, hepatocytes contain 
approximately two-hundred fold more ai-AT mRNA transcripts per cell than do 
mononuclear phagocytes, including blood monocytes and alveolar macrophages, 
suggesting that the liver is the major site of apA T biosynthesis (Perlino et al., 1987).
The path o f apA T biosynthesis is typical of a secretory glycoprotein (figure 2.4). The 
apA T is translated on ribosomes bound to the endoplasmic reticulum (ER). As the ap  
AT polypeptide is synthesised, it proceeds through the membrane of the ER to the 
lumen, a process thought to be directed by the 24 amino acid N-terminal signal peptide 
on the newly synthesised apA T molecule. Within the cisterna of the rough ER, the 
three carbohydrate side chains are added as the protein begins to fold into its three- 
dimensional configuration. Like other N-linked oligosaccharides, the carbohydrate 
side chains o f apA T are initially added in the form of a branched oligosaccharide, 
containing nine mannose residues, among other components. Once linked to the a p  
AT molecule, the so-called “high mannose” side chains are trimmed and the protein is 
translocated to the Golgi apparatus, where the side chain processing of the 
oligosaccharides is completed, to form the final “complex” type of side chains found 
on mature apA T (Pfeffer&Rothman, 1987).
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Figure 2.4: Processes involved in the normal biosynthesis of ai-AT. In the nucleus, 
the mRNA precursor is transcribed from the gene. After splicing and translocation, 
the ai-AT is translated on the rough ER. The newly synthesised polypeptide chain is 
secreted into the cisterna of the rough ER, the signal peptide is cleaved, and the 
carbohydrate side chains are added as the protein folds. The initial “high mannose” 
carbohydrate side chains undergo proximal trimming, and the protein is then 
translocated to the Golgi apparatus. Within the Golgi, terminal modification of the 
carbohydrate side chains yields a mature 550-kDa protein (from Brantly el al., 1988)
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2.1.3 Genetic basis for oq-antitrypsin deficiency
The ai-AT locus is pleomorphic, with approximately 75 alleles identified. The op-AT 
alleles are conveniently categorised as “normal” and “at risk”, (table 2.1). By 
convention, a normal allele is one that, when inherited in a homozygous fashion, is 
associated with serum ai-AT levels of 20-53 pM. The at-risk alleles relevant to a risk 
for lung and liver disease include “deficient” alleles (an allele that when inherited in a 
homozygous form is associated with serum levels < 20 pM) and “null” alleles (no oq- 
AT in serum attributable to that allele), (Crystal, 1990).
The PI (protease inhibitor) variants, initially identified primarily by the method of acid 
starch gel electrophoresis, were named in order of their mobility: F (fast), M 
(medium), S (slow), and Z (the most cathodal). There are many inherited variants of 
cq-AT (figure 2.5). PPM , which can be further classified into subtypes, is the most 
common allele in all populations. The PI*S allele reaches polymorphic frequencies in 
many populations, as does the PI*Z allele, which produces a deficiency of op-AT. In 
addition to common variants of op-AT, more than 60 rare variants of op-AT have been 
identified. The amino acid sequence has been identified for a number of types of oq- 
AT, either directly or by DNA sequence analysis. An alanine-valine substitution at 
amino acid position 213, noted by amino acid sequencing was further identified by 
DNA studies of both Z and M l. The alanine substitution is found in about 34% of 
PI*M1 alleles and differentiates two subtypes of M l: Ml (Ala213) and M l (Val213). 
The PI*Z allele has the Ala213 substitution. However, PI types M2, M3, and S all have 
valine at position 213 (Nukiwa et al., 1987).
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Table 2.1: Sequence differences among the “normal” and the “at risk” alpha-1
antitrypsin alleles.
C a te g o r y A lle le B a se  a lle le M u ta t io n  
s ite  (e x o n )
S e q u e n c e  c o m p a r e d  to  b a se  a lle le
Normal M l (Ala213)
M l(Val213) M l(Ala213) III Ala213 GCG -*• Val GTG
M3 M l(Val213) V Glu376 G A A -* Asp GAC
M2 M3 11 Arg101 CGT —  His CAT
M4 M l(Val213) II Arg'01 CGT - >  His CAT
a^lhambra Unknown Unknown Lys—> Asp
F M l(Val213) III Arg223 CGT ->■ Cys TGT
Saint Albans M l(Val2'3) V Asp341 GAC - »  Asn AAC
III Asp256 GAT — Asp GAC
V  munich M l(Val213) II Asp2 GAT - >  Ala GCT
X M l(Val213) III Glu204 - *  Lys
C^hristchurch Unknown V Glu363 -► Lys
At risk z M l(Ala213) V Glu342 GAG Lys A AG
s M l(Val213) III Glu264 GAA - >  Val GTA
M h e e r le n M l (Ala213) V Pro269 CCC Leu CTC
m^alton M2 II Phe52 TTC —  delete TTC
m^ineral springs M l (Ala213) II Gly67 GGG Glu GAG
p^rocida M l(Val213) 11 Leu41 CTG - >  Pro CCG
M nichinan Unknown II Phe52 TTC —  delete TTC
Gly148 GGG - >  Arg AGG
i M l(Val213) II Arg39 CGC -<■ Cys TGC
Plowell M l(Val213) III Asp256 GAT - >  Val GTT
b^ethesda M l(Ala213) V Ala336 GCT —> Thr ACT
Nllllgranite falls M l(Ala213) II Tyr160 TAC -► delete C ^ 5 ’ shift—» 
stop TAG
NullBellingham M l(Val213) III Lys217 A AG - »  stop217 JAG
Nullmatawa M l(Val213) V Leu353 TTA —  Insert T -► Phe3iJ 
TTT —  3’ shift stop376 TAG
Nulljsoia di procida Unknown II-V Delete lOkb including exons II-V
Nulling kong M2 IV Leu318 CTC —  delete TC - »  5’ shift 
—> stop334 TTA
Nlll Bolton Unknown V Pro362 CCC - >  delete C — 5’ shift — ■ 
stop373 TAA
Nlllldevon Unknown II Gly115 — Ser
Nulliudwiushafen M2 II He92 ATC Asn AAC
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Figure 2.5: Diagram of selected anodal (top row) and cathodal (bottom row) PI 
variants as revealed by isoelectric focussing in polyacrylamide gels. The solid lines 
indicate the positions of the two major bands of M l . Anode at top. (From Cox, 1995)
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The distribution of the PI alleles has now been determined for many populations. In 
all populations, PI*M is the most common allele. PI*M1 is distributed in all 
populations with the highest frequency in all populations studied, with PI*M2 the next 
most frequent, while PI*M3 is found to be relatively uncommon. The additional 
subtype allele PI*M4 has been described in several populations at a frequency of 0.002 
to 0.050 (Cox, 1995). In many studies, no differentiation was made between PI types 
M3 and M4, since isoelectric focussing does not easily separate these alleles. The 
PI*S allele is rare or absent in black and oriental populations, but show the highest 
frequency in Spain and Portugal, a lower frequency in France, and low generally in 
other parts o f Europe. The frequency of PI*Z is highest in Scandinavian countries, 
and the allele is present throughout white populations including those of the Middle 
East, and is absent from oriental and black populations, except in those populations 
known to have a white admixture, as in the United States (Cox, 1995).
The most common of the deficiency alleles is PI*Z, and most individuals with oq-AT 
deficiency are of PI type ZZ. The estimated frequency of the PI*Z allele in North 
American white populations is 0.0122, corresponding to a frequency of PI ZZ 
homozygotes of 1 in 6 700 (Cox, 1995).
The Z variant differs from the Mi (Ala213) by the substitution of lysine for glutamic 
acid at position 342. This mutation reduces the stability of the molecule in its 
monomeric form and predisposes to a novel protein-protein interaction between the 
reactive centre loop of one molecule and the A P sheet of a second (Lomas et al., 
1992). This “loop-sheet” polymerisation interferes with the secretion of the molecules
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from the hepatocytes and macrophages and results in decreased plasma levels of 1 0%- 
15% of normal.
The S variant differs from the Mi (Val213) by the substitution of valine for glutamic 
acid at the 264 position (Brantly et al., 1988). This mutation also leads to the 
production of polymers (Elliot et al., 1996). This effect reduces plasma ai-AT 
concentrations to 60% of normal.
The S and Z variants have been associated with emphysema (Brantly et al., 1988), 
liver disease (Brantly et al., 1988), panniculitis (Pinto et al., 1993) and asthma (Colp 
et al., 1993). Elliot et al. (1998) provided the first demonstration of Zai-A T polymers 
in the lungs of patients with emphysema. The inactivated ai-AT is unable to play any 
role in the anti-proteinase screen, and this serves to exacerbate lung disease associated 
with plasma deficiency of the Z mutation of a r AT (Elliot et al., 1998).
However, several studies suggest that individuals with certain ai-AT phenotypes may 
be predisposed to developing asthma. Gaillard et al. (1992) reported an increased 
prevalence o f the non-deficient M2M2 ai-AT phenotype in white asthmatics in South 
Africa, while an increased prevalence of the Z allele of ai-AT was found to be 
associated with severe asthma in Swedish children (Cox, 1994; Walls, 1995). 
Interestingly, a heterozygote advantage has been suggested to account for the high 
incidence o f the S and Z ai-AT alleles in the European population. These alleles have 
been implicated in protection against pulmonary tuberculosis (Carrell, 1984).
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2.1.4 Loop-sheet polymers and ai-antitrypsin deficiency
The Z mutation of ai-AT is located at residue P 17 (17 residues proximal to the Pi 
reactive centre) at the head of strand 5 of the A [3-sheet and the base o f the mobile 
reactive centre loop. It had been predicted that the mutation would act to open the A 
sheet, thereby favouring spontaneous loop into P-sheet polymerisation (Lomas, 1996). 
Functional studies showed that Z ai-AT was more unstable and was able to polymerise 
at 37 °C under physiological conditions (Lomas et al., 1992). The rate is accelerated 
by raising the temperature to 41 °C, and can be blocked by exogenous reactive loop 
peptides that compete with the loop for A-sheet annealing. The role o f this 
phenomenon in vivo was clarified by the demonstration that polymers with identical 
microscopic appearance could be isolated from the liver of a Z ai-AT homozygote 
(Lomas, 1996).
Although many ai-AT deficiency variants have been described, only two other 
mutants o f aj-AT have similarly been associated with plasma deficiency and hepatic 
inclusions: ai-antitrypsin Siiyama (Ser53Phe) and a 1-antitrypsin Mmalton (52Phe 
deleted). ai-Antitrypsin Siiyama was first described in 1993 in Japan, and although 
rare it is the commonest form of ai-AT deficiency in that country (Seyama et al., 
1995). The abnormal ai-AT isolated from the plasma of a Siiyama homozygote was 
all in the form of long chains of inactive loop-sheet polymers (figure 2 .6a).
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The other mutation resulting in severe deficiency, ai-AT Mmalton, has been reported 
sporadically in the UK and Canada (Frazier et al., 1989; Curiel et al., 1989). Once 
again, the isolation of op-AT from the plasma of an Mmalton null heterozygote yielded 
both polymeric and monomeric antitrypsin. The polymers were shorter than those of 
Siiyama ai-AT, but showed the same characteristic resistance to unfolding in 8M urea 
(Lomas et al., 1995).
The temperature and concentration dependence of polymerisation may account, along 
with genetic factors, for the heterogeneity in clinical features. As op-AT is an acute- 
phase protein, its concentration will rise during episodes of inflammation. At these 
times, the formation of polymers is likely to overwhelm the degradative pathway, 
thereby exacerbating hepatic inclusions and the associated hepatocellular damage 
(Lomas, 1996).
Crystals of recombinant protein were grown and the structure of op-AT solved to 2.9 
A. This structure shows the mobile loop trapped in an extended confonnation that fits 
comfortably into the binding pocket of the proteinases trypsin and chymotrypsin 
(Elliot et al., 1996). This conformation of the loop is in the form of a (3-pleated strand, 
which also provides an explanation for the ready formation of loop-sheet polymers, as 
this strand configuration fits easily into the A P-pleated sheet of ai-AT (figure 2.6b) to 
form a dimer that can extend as trimers, tetramers and so on to as many as 20 
molecules in length (figure 2.6c). These filaments then tangle within the endoplasmic 
reticulum of the hepatocyte to form the insoluble inclusions that are characteristic of Z 
cp-AT deficiency (Lomas, 1996).
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The reactive loop’s ready adoption of a (3-strand conformation also accounts for the 
intimate association of another serpin, ai-antichymotrypsin, with another p-pleated 
structure that of amyloid plaques of Alzheimer’s disease (Ma et al., 1994). The 
phenomenon of loop-sheet polymerisation is not restricted to oq-AT and has now been 
reported to account for the deficiency of other mutants of the serpins associated with 
angioedema (Cl-inhibitor), (Aulak et al., 1993; Eldering et al., 1995), emphysema 
(antichymotrypsin), (Faber et al., 1993) and thrombosis (antithrombin), (Bruce et al., 
1994).
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Figure 2.6: (a) Loop-sheet polymers of ai-AT isolated from the plasma of a Siiyama 
a r AT homozygote. This point mutation favours the formation of long chains of 
polymers as well as circlets (inset). These polymers tangle in the liver to form 
insoluble inclusions that predispose to liver damage; (b) Crystal structure of a r AT 
provides strong support for the loop-sheet linkage being between the (3-pIeated 
reactive centre loop of one molecule (red) and the A p-pleated sheet (yellow) of the 
next. These dimers extend to form long chains shown in (c) as alternating yellow, blue 
and red ct|-AT molecules (from Lomas, 1996).
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The development of the polymerase chain reaction (PCR) technique for nucleic acid 
amplification has had a major impact on many diverse areas of both basic and clinical 
research. Since its inception (Saiki et ah, 1989), reports on a wide variety of 
applications for PCR have received much attention in scientific and medical literature. 
This technology has been shown to have a vast application to the diagnosis of human 
disease including such diverse areas as infectious disease, genetic disorders and cancer 
(Arends & Bird, 1992; Gunther et al., 1993).
Basic Principle of PCR
PCR is a chemical method of exponentially increasing the concentration o f a specific 
nucleic acid sequence relative to that of other nucleic acid sequences in the reaction 
mixture (Bloch, 1991). The principle of the method is shown in figure 2.7.
2.1.5 Amplification of DNA: The Polymerase Chain Reaction
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Figure 2.7: Schematic diagram of (a) a single PCR cycle and (b) the generation of the 
short template over the first few amplification cycles (from Bloch, 1991).
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2.2 Materials and Methods
2.2.1 Materials
The following materials were obtained from Promega (Madison, WI): Agarose, 
acrylamide, dNTPs, Taq DNA polymerase, Hae III restriction endonuclease and 
proteinase K; the oligonucleotide primers were synthesised by Genosys 
Biotechnologies Inc. (Woodlands, TX); the bis-acrylamide, ammonium persulfate and 
TEMED were from BioRad (Hercules, CA); the Ampholines were supplied by 
Pharmacia (Uppsala, Sweden); the double-distilled water was from SABAX 
(Johannesburg); PCR tubes were supplied by Laboratory and Scientific Equipment Co. 
(Johannesburg); the Coomassie Brilliant Blue and the mineral oil were from Sigma 
Chemical Co. (St. Louis, MO); the Whatman filter paper was from Whatman 
International (England); the DNA molecular weight markers were supplied by 
BioVentures Inc (Murfreesboro, TN); the 2ml eppendorf tubes were supplied by Treff 
Laboratories (Switzerland); all other reagents used were of analytical grade Merck 
(Darmstadt, Germany).
2.2.2 Subjects
Thirty-three white asthmatic patients, 30 black asthmatic patients, 54 white controls 
and 36 black controls were used. The asthmatic patients were recruited from the 
Asthma and Respiratory Clinics of Hillbrow and Johannesburg Hospitals and from 
Krugersdorp Hospital (Paediatrics). The controls were either blood donors who
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presented themselves at the South African Blood Transfusion Services in 
Johannesburg or outpatients at the Johannesburg Hospital Paediatric Nephrology 
Clinic. The patient with the novel polymorphism and the fifty controls used for the 
polymorphism study was from the Respiratory Medicine Unit, Cambridge Institute for 
Medical Research, Cambridge, United Kingdom. None of the controls had a history of 
atopy or any disease process associated with the respiratory system. All individuals 
who participated in the study were 4-45 years of age, and each subject gave informed 
consent (or in the case of minors, consent was obtained from parents) to participate in 
the study. The Committee for Research on Human Subjects of the University of the 
Witwatersrand approved this protocol.
2.2.3 Asthma and Atopy
Each patient had a history of bronchial asthma as defined by the American Thoracic 
Society, namely a history of transitory or prolonged episodes of dyspnea, coughing and 
wheezing, but was otherwise healthy (American Thoracic Society Statement, 1962). 
The diagnosis was confirmed in each patient by the finding of at least one of the 
following: a forced expiratory volume in one second (FEV) < 70% of the predicted 
value with reversibility of 2 0 % or more following inhalation of a P 2-adrenergic 
bronchodilator, or a fall in peak expiratory flow rate of at least 2 0 % during a 
standardised exercise test. Atopy was defined as a positive skin prick test at least 
2mm greater than a negative control and a positive specific IgE titre (>0.35kU/L) or a 
high concentration of total serum IgE greater than published normal values for 
children, or greater than 400kU/L in adults. Asthma was classified as mild, moderate
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or severe using the classification of Scheffer (1991).
2.2.4 DNA extraction
The polymerase chain reaction (PCR) requires a source of nucleic acid (DNA or RNA) 
for amplification. The technique is highly tolerant of impurities in the DNA sample 
that is being amplified, and the degree of nucleic acid purification necessaiy before 
PCR-amplification depends on the complexity and chemistry of the sample matrix, as 
well as on the target sequence. It is usually necessary to deproteinase a biological 
sample to ensure the removal o f extraneous proteases, nucleases and phosphatases that 
might destroy reactants that are crucial for the amplification reaction (Bloch, 1991).
Conventional DNA extraction methods usually employ detergents to solubilise cell 
components and proteolytic enzymatic degradation of DNA-bound proteins (Maniatis 
et al., 1982). This step is followed by extraction with organic solvents such as phenol 
and precipitation of the nucleic acid with ethanol (Maniatis et al., 1982). Although 
this standard technique is PCR-compatible, a variety of faster, simpler methods have 
emerged. The method developed by Higuchi (1989), and which was used in the 
present study, allows for the efficient release of DNA from nucleated blood cells. It 
obviates the use o f organic extraction and ethanol precipitation, and instead allows for 
the direct addition of cells or nuclei to a PCR-compatible solution that contains 
nonionic detergents (which lyse cell membranes by removing integral proteins) and 
proteinase K (which can be inactivated by heat).
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This method efficiently releases DNA from ± 3x 105 nucleated cells, and the DNA can 
then be amplified by PCR with little or no inhibition (Higuchi, 1989). Porphyrins, 
which are derived from heme present in blood, may be the most potent cell 
components inhibitory to PCR and in order to separate porphyrins from nuclear DNA, 
this extraction method lyses cell membranes and pellets nuclei and cell debris. A 
number o f pelleting and washing steps remove haemoglobin that is released from 
blood cells, as well as RNA and cytoplasmic DNA. The resulting pellet, containing 
nuclear DNA, is finally resuspended in proteinase K/detergent solution. The final 
yield is approximately 20pg of nuclear DNA/lml of blood (Appendix I).
The integrity of the extracted DNA was determined by electrophoresis in 0.7% (w/v) 
agarose gels in lxTBE buffer (0.089M Tris-borate, 0.002M EDTA, pH 8.2) at 100V 
for 20-30 min (Appendix II).
2.2.5 ai-AT phenotype study
All blood specimens were collected into EDTA-containing tubes. Plasma from each 
sample was separated on the day of collection and stored at -60°C until analysed, cq- 
AT phenotypes were identified by isoelectric focussing in polyacrylamide gels. 
Polyacrylamide gel electrophoresis is one of the most useful methods for the analysis 
of protein mixtures. Isoelectric focussing (IEF) is used for the fractionation of 
molecules that only differ in net charge (Andrews, 1987). The technique is performed 
in non-sieving media (such as polyacrylamide gels) and is capable o f very high 
resolution, especially when shallow, immobilised pH gradients are used (Andrews,
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1987). In addition, macromolecules that differ in their isoelectric point by as little as 
0.001 pH units can be separated efficiently (Robard et al., 1974).
The technique is based on a moving boundary, and amphoteric substances (e.g. amino 
acids and peptides) are separated in an electric field which has both pH and voltage 
gradients (Davis, 1986). The anode region has a lower pH than the cathode area and a 
suitable pH is maintained between the electrodes - the pH range is chosen such that the 
molecules being separated have their isoelectric points within that range (Davis, 
1986). Substances are positively charged at pH regions below their isoelectric point 
and they migrate toward the cathode, but as they migrate, the pH increases and the 
substances become zwitterions with no net charge so that migration stops (Davis, 
1986). Similarly, substances which at first occur at pHs above their isoelectric point is 
reached, at which stage migration ceases (Davis, 1986). As a result, amphoteric 
substances are focussed into narrow stationary bands (Davis, 1986). IEF is a principal 
technique for the analysis and characterisation of proteins, peptides, glycoproteins, 
lipoproteins, phosphoproteins, cell membrane proteins, isoenzyme patterns and studies 
with nucleic acids and glycosaminoglycans (Andrews, 1987). IEF is thus used in 
clinical, forensic and genetics laboratories for the separation and identification of 
serum proteins (Davis, 1986).
Detection of proteins after electrophoresis is most commonly done by staining with the 
organic dye Coomassie Brilliant Blue, the principle being that electromorphs take up a 
general protein stain (Constans et al., 1980).
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This detection method is common due to the fact that it produces little background 
staining, because the colloidal form of the dye does not enter the gel (Nivinskas & 
Cole, 1996). The ai-AT phenotypes were identified using the following modification 
of the IEF method by Constans et al. (1980). A 0.5mm thick gel was prepared by 
dissolving 0.97g acrylamide, 0.03g bis-acrylamide and 2.67g sucrose in 19.3 mL of 
water. One millilitre of Ampholines, pH 4.2-4.9 and 30 pL of TEMED were added 
and the solution was degassed for 3 min. Thereafter 1 mL of a freshly prepared 10% 
ammonium persulfate stock solution was added and the gel was poured into a 
124x257x0.5mm LKB Multiphor gel mould. The gel was allowed to set for 30 min at 
room temperature, and thereafter refrigerated (4°C) for 15 min. Electrode strips 
(17mm Whatman or LKB paper wick 1850-911) were soaked with 0.1 M sodium 
hydroxide (0.4 g/100 mL distilled water) for the cathode (the negative electrode) and 
0.04 M phosphoric acid (0.5 mL/100 mL distilled water) for the anode (the positive 
electrode). The gel was pre-focussed for 30 min at 800 V, 10 mA, 10 W. The 
samples were applied on paper inserts (17 mm Whatman) to the cathode end of the gel 
and were focussed for 45 min at 500 V, 8 mA, 8 W. The inserts were then removed 
and the gel focussed for a further 1 hr 45 min at 1200 V, 14 mA, 14 W. Thereafter, 
the bands were sharpened for 45 min at 2500 V, 14 mA, 8 W. After migration, the gel 
was stained in a 0.1% solution of Coomassie Brilliant Blue (45% methanol, 10% 
glacial acetic acid) for 1 hr at 37°C and rinsed in distilled water. Following destaining 
(45% methanol, 10% glacial acetic acid), the phenotypes of selected aj-AT variants 
observed in human sera of asthmatic patients and control subjects were read (figure 
2.8).
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M,S M,M, M,M, M,V M,M, M,M, M,M, M,M, M2S M,M2 ZZ M,Z M,M, M,M, M,M, M,M, M,M, M,V M,M, M,M, M,M2M,M,
Figure 2.8: Selected a,AT variant observed in human sera using isoelectric 
focussing in ultra- thin polyacrylamide gels. The anode is at the top.
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2.2.6 Restriction fragment length polymorphism
Total genomic DNA was extracted from EDTA-containing whole blood according to 
the Higuchi method (1989), modified as previously described. The polymerase chain 
reaction (PCR) was used to amplify exon II of the oq-AT gene in ten asthmatic patients 
and fifty control individuals. The following primers were used:
P I : 5' -AGT TCG CCT TCA GCC TAT AC- 3'
P2: 5' -GAA GCT AGT GGA TAA GTT- 3'
The amplified sequence is 296 bp long. Amplification (by PCR) was performed in a 
reaction volume of 63 pL, containing 1 pg of genomic DNA, 0.2 mM each of dATP, 
dCTP, dGTP and dTTP, 10 mM Tris-HCl buffer (pH 8.3), 50 mM KC1, 1.5 mM 
MgCfi (0.01% gelatine) and 1 pM each appropriate amplification primer (Appendix 
II).
The reaction mixture containing all the components, except the Taq DNA polymerase, 
was overlaid with 50 pL mineral oil and heated to 94°C for 10 min in a Hybaid DNA 
thermal cycler (Hybaid, UK). Following a cooling step, which reduced the sample 
temperature to 50°C, 1 unit of Taq DNA polymerase was added. The samples were 
then processed through 40 cycles of: denaturation at 94°C for 20 secs, annealing at 
50°C for 20 secs and extension at 74HC for 30 secs. The final step was one of 
extension at 74°C for 10 min.
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Restriction analysis of the amplified fragments of exon II of the oq-AT gene was 
performed as follows:
20 pL of the PCR reaction mixture was digested with 2 units of Hae III (lU /pl) and 
incubated overnight at 37°C. Resolution of the restricted products was performed by 
electrophoresis in 4% agarose gels run at 70V for 2 hours. Following electrophoresis, 
gels were stained with ethidium bromide (0.5 pg/mL) in lxTBE buffer (0.089 M Tris- 
HCL, 0.002 M EDTA, pH 8.2), viewed under UV illumination (302nm) and 
photographed with a Polaroid CU-5 Land camera.
Direct sequencing was carried out using the ABI Prism Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit and the sequencing products were separated and 
analysed in an ABI 310 DNA sequencer (Appendix IV).
2.2.7 PCR of ai-AT exons II-V
Amplification (by PCR) was performed in a reaction volume of 63 pL, containing 1 pg 
of genomic DNA, 0.2 mM each of dATP, dCTP, dGTP and dTTP, 10 mM Tris-HCl 
buffer (pH 8.3), 50 mM KC1, 1.5 mM MgCl2 (0.01% gelatin) and 1 pM each 
appropriate amplification primer (Appendix II). Reaction conditions included 30 
cycles of a denaturation step at 94°C for 1 minute, annealing at 60°C for 1 minute 
(exon II) or 52 °C for 1 minute (exon III, IV, V) and extension at 72°C for 2 minutes. 
PCR products were electrophoresed on 2% agarose gels at 80V for 60 minutes. 
Products were visualised by UV transillumination.
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2.2.8 Direct DNA cycle sequencing of PCR products
PCR products were pre-treated with 1 OU/pl Exonuclease I and 2U/pl Shrimp Alkaline 
Phosphatase (Amersham Life Science, Cleveland, Ohio, USA) and incubated at 37°C 
for 15 minutes. Pre-treatment enzymes were inactivated by incubation at 80°C for 15 
minutes. PCR products were sequenced using a Thermosequenase Radiolabelled 
Terminator Cycle Sequencing Kit (USB, Cleveland, Ohio, USA) and a -P 33 ddNTP’s 
(USB, Cleveland, Ohio, USA). Cycle sequencing was performed on a Hybaid DNA 
thermal cycler (Hybaid, UK) with 30 cycles of 95°C for 1 minute, 45°C for 1 minute 
and 72°C for 2 minutes. Reactions were stopped with 4pl stop solution. Sequencing 
products were denatured at 96°C for 10 minutes and electrophoresed at 60W for 2-4 
hours with IX glycerol tolerant buffer (GTB) on denaturing 8% w/v polyacrylamide- 
urea gels. Gels were fixed, dried and autoradiographed (Appendix III).
2.2.9 Elastase inhibitory assay
The serum elastase inhibitory capacity (EIC) was determined according to the method 
described by Gaillard et al (1987) using porcine pancreatic elastase and succinyl-p- 
nitroanilide as a chromogenic substrate. The absorbance was measured at 405 nm.
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2.3 Results
During the course of this study, routine sequencing revealed an interesting and unique 
polymorphism (figure 2.9) in an asthmatic individual from the United Kingdom. This 
sequence has a polymorphic Hae III recognition site. The fragment will either be cut 
into two (142 bp + 115 bp) or three (142 bp + 133 bp + 115 bp) fragments following 
digestion with the enzyme Hae III (figure 2.10). The novel polymorphism identified in 
exon II (471) CTG—»TTG was found in the heterozygous state (figure 2.10) with the 
common normal M3 base allele in a Caucasian female with normal cp-AT plasma 
level (1.1 mg/ml; normal range 0.9-1.8 mg/ml) and asthma from the United Kingdom. 
This polymorphism was not detected a total of fifty controls matched for age and sex 
from the United Kingdom.
A five year old Caucasian boy presented with an inability to exercise due to severe 
wheezing and breathlessness. He also complained of early morning wakening and 
episodes of nocturnal wheezing. His family doctor had started budesonide 100 pg 
twice daily without significant benefit and the patient had required several courses of 
oral prednisolone. On examination the chest was hyper-inflated. The chest radiograph 
was normal, but pulmonary function testing revealed a baseline FEV1 of 1.76 L that 
fell to 1.44 L (18% reduction) after exercise. A diagnosis of asthma was made and he 
responded well to treatment with inhaled fluticasone 250 pg and salmeterol 25 pg both 
twice daily. The child’s mother but not his father was also noted to have had asthma 
but no other clinical details were available.
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The child’s serum IgE was significantly elevated at 804 KU/L (normal range 0-71). 
He had a Rast class 2 to house dust (0.93 KU/L; rast class 0<0.35) and dog dander 
(0.85 KU/L), a class 5 rast to both Timothy grass (>100 KU/L) and mixed South 
African trees (Olive, Willow, Pine, Eucalyptus and Acacia); 77.7 KU/L, a rast class 4 
to mixed South African weeds (includes Marguerite, dandelion, plantain, goosefoot 
and golden rod); 21.1 KU/L, and a rast class 6 to Bermuda grass; >100 KU/L.
Baseline ai-AT plasma levels were 1.31 g/1 and 1.44 g/1 for the child and mother 
respectively (normal range 0.9-1.8 g/1). Isoelectric focussing revealed an unusual 
faster band, which was seen to migrate towards the anode for both the child and 
mother. The new variant was characterised by direct genomic sequencing and was 
found to have a point mutation C—>A corresponding to amino acid position 15 of the 
N-terminus resulting in the substitution of a Histidine for an Asparagine on an Ml 
(Val ) base allele. The elastase inhibitory capacities for the child and mother with 
the M I E ( j o h a n n e s b u r g ) phenotype (figure 2.11) were 43.97 KU/g and 50.38 KU/g 
respectively. Five other non-related asthmatic patients showed an identical IEF 
migration pattern to the M 1 E ^ o h a n n e s b u r g ) phenotype discussed (figure 2.12). Direct 
sequencing confirmed the mutation being present in these patients but not controls and 
again the mutation did not affect baseline plasma levels or the elastase inhibitory 
capacities in these asthmatic patients.
Isoelectric focussing identified another new variant, the M 1 N (j o h a n n e s b u r g ) (figure 
2.13) in four non-related Caucasian asthmatic individuals, one of whom suffered with 
severe allergies. The new variant although not associated with any deficiency was
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characterised by direct genomic sequencing and was found to have two mutations that 
were in linkage with each other. The first is a CAG—»CAC mutation corresponding to 
amino acid position 97 in exon II resulting in the substitution of a Glutamine for a 
Histidine on an M l (Val 213) base allele (figure 2.14). In addition to this mutation, 
sequencing of exon II in these patients also revealed a base change as a result o f an 
insertion o f a G at position 95 (figure 2.15).
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Figure 2.9: Sequence o f polymorphism identified in exon II 
(471) CTG — ► TTG
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Figure 2.10: Hae III restriction o f exon II o f the a,AT gene showing a 
homozygous individual (lane4), a heterozygous individual (lane3), lane 2, an 
unrestricted PCR product, lane 1, molecular weight marker.
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Figure 2.11: The M,E (JohannKburg) a,AT variant observed using isoelectric focussing in 
ultra thin polyacrylamide gels. The anode is at the top.
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Figure 2.12: Selected aj-AT variants observed in human sera using isoelectric 
focussing in ultrathin polyacrylamide gels. The anode is at the top.
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M,M, M,N M,C M,M,
Figure 2.13: The M,N a , AT variant observed using
isoelectric focussing in ultra thin polyacrylamide gels. The 
anode is at the top.
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A C G T
Figure 2.14: DNA Sequence showing the CAG—► CAC 
mutation of the variant o f a , AT.
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A C G T
Figure 2.15: Sequence showing the insertion of the extra G 
linked to the CAG —► CAC mutation o f the M,N(Johaimcsburg) 
variant of a.] AT
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2.4 Discussion
The differences between ai-AT phenotypes involve simple amino acid substitutions. 
The two most common M l phenotypes differ by having either valine or alanine at 
position 213. The normal M2 subtype differs from M l(V al213) by two substitutions: 
histidine for arginine at the 10 1 position and aspartic acid for glutamic acid at the 376 
position (Crystal et al., 1989). Two important deficiency variants, Z and S, are 
associated with deficient plasma op-AT levels, which, in the case of the former, 
predisposes to emphysema. The Z molecule differs from the M l (Ala213) by the 
substitution of lysine for glutamic acid at the 342 position, whereas the S molecule 
differs from the M l(Val ) by the substitution of valine for glutamic acid at the 264 
position (Brantly et al., 1988).
The Z allele is associated with markedly reduced plasma levels of ai-AT, directly as a 
result of the Glu342->Lys342 substitution, which appears to interfere with the salt bridge 
to Lys290 causing a change in the configuration of the molecule (Loebermann et al., 
1987). It is also clear that the Z molecule is qualitatively deficient, being unable to 
maintain a complex with elastase (Ogushi et al., 1987). The precise mechanism of 
this abnormality is not understood, but it may also relate to the altered three 
dimensional configuration of the molecule. The S allele is also associated with low 
plasma op-AT levels, apparently due to molecular instability with intracellular 
destruction (Curiel et al., 1988). It is functionally normal and does not appear to 
confer a risk of emphysema even in its homozygous (SS) form (Ogushi et al., 1988).
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The mechanism by which the S mutation results in plasma deficiency is unclear and 
has been attributed to increased clearance, aberrant protein folding and intracellular 
degradation (Elliott et al., 1997). It has been suggested that the deficiency of S 
antitrypsin result from a slow transition to form dimers and short chain polymers that 
result in a mild reduction in secretion from the hepatocyte and an increased rate of 
turnover in the plasma. The crystal structure of S antitrypsin shows that the S 
mutation breaks the Glu264->Tyr38 salt bridge which would predictably perturb the 
Phe52-*Ser53 region at the commencement of the |3 helix and hence favour 
polymerisation as occurs more dramatically with the Siiyama and Mmalton mutants 
(Elliot et al., 1997). Among populations of asthmatic patients, those heterozygous for 
the deficient apA T variants may have more severe disease as manifested by worse 
spirometric results, poor bronchodilator response and steroid dependency (Gaillard et 
al, 1992).
Several deficiency alleles have been reported in which the plasma concentration of ap  
AT is detectable against standards and is generally in the range of about 2 to 15 
percent of normal. All have an electrophoretic mobility different from that o f the PI Z 
variant (Cox, 1995). Just like the variants that we describe. PI Z a u g s b u r g  and PI 
Z w r e x h a m  have the Z  mutation as well as another benign amino acid difference. PI 
M m a l t o n  is associated with PAS-positive hepatocyte inclusions identical with those 
found in association with PI Z, and, like Z, the protein has a tendency to aggregate 
(Cox, 1995). PI M d u a r t e , first reported in a 48-year-old woman with severe bullous 
emphysema, migrates in acid starch gel and agarose similarly to PI M, and the 
isoelectric point is similar to that of M3, as determined by isoelectric focussing. PAS-
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D globules were present in the liver, indicating that this deficient variant also has, like 
Z, a defect in secretion from the liver (Cox, 1995). Individuals with rare deficiency 
alleles have the same risk for obstructive lung diseases as PI ZZ individuals. 
Furthermore, these PI types will produce ai-AT inclusions in the liver, particularly in 
heterozygotes, in the presence of an apparently normal M  phenotype. When 
isoelectric focussing is used, the M m a l t o n  aj-AT can be identified even in the 
presence of a normal M  allele. M d u a r t e  can be detected in a heterozygote with an S 
or Z allele but, depending on the degree of resolution with isoelectric focussing, may 
not be detectable in the presence o f a normal M allele (Cox, 1995). Although the PI* F 
allele is not associated with a decrease of ai-AT concentration, there is a suggestion 
that PI FM heterozygotes may be more susceptible to pulmonary function impairment, 
particularly when exposed to industrial pollutants. apA T of the F type, which has an 
extra cysteine residue, appears to have an increased tendency to oxidation, as shown 
by its altered electrophoretic pattern after ageing, and this increased tendency to 
oxidation may make PI FM individuals susceptible to lung destruction in a polluted 
environment (Cox, 1995).
The mutation that underlies the E ( j o h a n n e s b u r g ) and N ( j o h a n n e s b u r g ) does not affect 
baseline plasma oq AT levels or plasma elastase inhibitory capacity. Furthermore, the 
E ( j o h a n n e s b u r g ) His—>Asn mutation is in a poorly conserved region of the protein and 
is unlikely to affect the structure or function of otiAT. Nevertheless, like the M l Ala213 
and M2  alleles, ajA T E ( j o h a n n e s b u r g ) and N (j o h a n n e s b u r g ) may be in linkage 
disequilibrium with other key factors involved in the IgE-mediated inflammatory 
response.
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Association between non-Ml variants of aiA T and raised IgE levels were found in 68 
white patients and 59 black patients with gastro duodenal ulcer disease (Redelinghuys, 
2000). There have been a number of studies suggesting that atopy, asthma and 
bronchial hyper responsiveness are associated with heterozygosity for cystic fibrosis 
(CF) o f the pancreas (Gerrard, 1985), also 36 white patients with CF was significantly 
associated with variants of a i AT (Jamal, 2002). More recently 36 white F1IV positive 
patients and 52 black HIV positive patients were associated with genetic variation of 
aiAT. This also reinforces the association of the a i AT variants and raised IgE levels 
as it is known that these patients are atopic due to the Thl/Th2 shift (Nicholson, 
2004).
These observations together with the novel polymorphism described adds further 
support to the inflammatory and genetic basis of asthma. Knowledge of the molecular 
basis of variants and polymorphisms, both normal and pathogenic, can be useful for 
the identification of the residues most important for protein function.
The description of new aiA T variants, particularly in diverse heterogeneous 
populations, such as in the case of South Africa, provides evidence for the 
environmentally driven evolution of the aiA T gene.
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CHAPTER 3
STABILISATION OF THE SERPIN-PROTEINASE COMPLEX 
THROUGH CONSERVED INTERACTIONS
3.1 Introduction
Alpha-1 antitrypsin (ai-AT) is the most abundant circulating proteinase inhibitor and 
the archetypal member of the serine proteinase inhibitor or serpin superfamily. The 
serpins bind to and inhibit target proteinases to control proteolytic cascades and to 
protect the tissues from extraneous enzymatic attack (Carrell et al., 1982). In 
particular a\-antitrypsin inhibits the enzyme neutrophil elastase that is released at sites 
of inflammation (Beatty et al., 1980).
The complex between ai-antitrypsin and neutrophil elastase is extremely stable such 
that it is considered to be almost irreversible (Lomas et al., 1993). This irreversibility 
of inhibition achieved by the serpins has made them principal inhibitors controlling 
both intra- and extracellular proteolytic pathways. In human plasma, antithrombin 
controls coagulation, Cl-inhibitor controls complement activation and the inhibitors of 
plasmin and its activators control fibrinolysis (Huntington et al., 2000). There have 
been many unsuccessful attempts over the past 20  years to crystallise the serpin- 
protease complex however, the recent crystal structure of a  i-antitrypsin bound to 
trypsin has allowed us to clarify the mechanism of stability between serpin and 
proteinase (Huntington et al., 2000).
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These crystallisation studies shows that ai-antitrypsin in activated trypsin by swinging 
it from the upper to the lower pole of the molecule accompanied by a marked 
disruption of the catalytic site of the proteinase. The two molecules were linked by an 
ester bond between Met358 of ai-antitrypsin and Seri 95 of trypsin. Close 
examination of the interface between the proteinase and the inhibitor revealed two 
additional interactions. There was a salt bridge between Lys328 of a  i-antitrypsin and 
Asp 194 of trypsin and hydrogen bonds between Asn314 of the inhibitor and the 
carbonyl oxygen’s of Aspl94, Trp215 and Ser214 of the proteinase (figure 3.1).
The contribution of these interactions to the stability of the complex is unknown. 
Moreover it is unclear whether these interactions are specific to the complex between 
aj-antitrypsin and trypsin or a general mechanism that stabilises other serpin- 
proteinase complexes. Support for a general mechanism comes from the observation 
that all serine proteinases have an aspartic acid at position 194 and all the other 
interactions are with main chain atoms.
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Figure 3.1: The conformational change of ai-antitrypsin following complex formation 
with a target proteinase. The proteinase docks with the inhibitor to form an initial 
Michealis complex (left). The Pt-P |' bond of the reactive loop is then cleaved and the 
proteinase is translocated to the lower pole of the molecule (right). The final complex 
is stabilised by an ester bond between the P, residue of ai-antitrypsin (Met358) and 
the proteinase active site serine (Seri95). The crystal structure also showed a salt 
bridge between Lys328 of ai -antitrypsin and Asp 194 of trypsin (inset) and hydrogen 
bonds between Asn314 of the inhibitor and the carbonyl oxygen’s of Asp 194, Trp215 
and Ser214 of the proteinase. Atomic coordinates have been deposited in the Protein 
Data Bank under accession number 1EZX (from Huntington et al., 2000).
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3.2 Materials and methods
3.2.1 Materials
The following were prepared by the media kitchen in the Laboratory o f Molecular 
Biology (MRC Centre, Cambridge, UK) according to the method of Sambrook 
(Sambrook et al., 1989): 2xTY (16g bacto-tryptone, lOg bacto-yeast extract and 5g 
NaCl per litre, pH 7.0 sterilised by autoclaving); ampicillin agar plates (15g agar, 8g 
NaCl, lOg bacto-tryptone, 5g yeast extract per litre, autoclaved then ampicillin added 
to a final concentration of lOOpg/ml before pouring). The T4 ligase and all the 
restriction enzymes were from New England Biolabs (UK) and the oligonucleotides 
were synthesised by Life Technologies Corp. The pQE31 expression vector, E.coli 
strain SG I3009 (PREP4) and Ni-NTA gel were from Qiagen Corp, the Hi-trap Q- 
Sepharose column was from Pharmacia (Uppsala, Sweden) and the chromogenic 
substrate S-2222 was from Chromgenix. Human neutrophil elastase, porcine trypsin 
and ampicillin were purchased from the Sigma Chemical Co (Poole, UK). Wizard 
DNA Maxipreps were from Promega (Southampton, UK); electroporation cuvettes 
(2mm gap) were from Equibio (Kent, UK). Dialysis membranes were from Medicell 
International Ltd (London, UK). The ABI Prism Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit was from Amersham (Buckinghamshire, UK). Both 
1.5ml and 2ml micro centrifuge tubes were from Starsted (Germany) and 15ml and 
50ml screw-cap tubes were from Falcon (New Jersey, USA). Vent polymerase was 
from New England Biolabs; Taq polymerase was from Promega (Southampton, UK).
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3.2.2 Mutagenesis, Expression and Purification of Recombinant a r antitrypsin
Human a,)-antitrypsin cDNA was excised from pWombat (a gift from Dr A. Zhou) 
using the BamHI and Hind III restriction sites (figure 3.2) and subcloned into pQE31. 
The Asn314Ala and Lys328Ala mutants were then prepared by site-directed 
mutagenesis using a two-step PCR. A third reaction incorporated both of the above 
changes to give the double mutant Asn34Ala/Lys328Ala (Appendix V).
The following primers were used for the site-directed mutagenesis:
314Asn—>Ala coding: 5'-AAGGTCTTCAGCGCTGGGGCTGACCTC-3'
non-coding: 5'- GCCCT AAGCTT ATTTTT GGGT GGGATTC ACC AC-3'
328Lys—>Ala coding: 5'- GAGGCACCCCTGGCGCTCTCCAAGGCC-3'
non-coding: 5'- GCCCTAAGCTTATTTTTGGGTGGGATTCACCAC-3'
All mutations were confirmed by automated DNA sequence analysis with an A B I310 
genetic analyser (Appendix IV). The rest of the ai-antitrypsin gene was also 
sequenced to ensure that there were no PCR errors.
Recombinant ai-antitrypsin was expressed with an N-terminal MRSHHHHHH-tag 
which can bind Ni-NTA agarose. Plasmids containing the wildtype and mutant a i- 
antitrypsin were transformed into SG13009 (PREP4) E.coli and the cells grown in 2 
litres of 2xTY media in a shaking incubator at 37°C until the ODgoo was between 0.6-
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0.9. IPTG was then added to a final concentration of ImM and the temperature 
lowered to 30°C for a further 3 hr. The cells were collected by centrifugation, 
resuspended in buffer A (lOmM phosphate buffer, pH 8.0; 0.5M NaCl; ImM p- 
mecaptoethanol), disrupted by sonication and the supernatant then loaded onto a 20mL 
Ni-NTA column. After washing to baseline with buffer A, the bound protein was 
eluted with 0-0.2M imidazole in buffer A. The fractions were collected, dialysed 
overnight against buffer B (lOmM Tris-Cl, pH8.0; ImM p-mecaptoethanol) and 
loaded onto a Hi-trap Q-sepharose column (5mL). The protein was then eluted with a 
NaCl gradient (0-0.5M) in buffer B. Recombinant ai-antitrypsin eluted as the major 
peak at approximately 0.2M NaCl (figure 3.3). The fractions were pooled and the 
protein concentration determined spectrophotometrically using the extinction 
coefficient A280nm1%5.3 (Pannell et al., 1974). The samples were aliquoted, snap- 
frozen in liquid nitrogen and stored at -70°C.
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Figure 3.3: Typical elution profile of recombinant wildtype and mutant a,-antitrypsin 
protein. Samples under the peak were positive for ot|-antitrypsin on rocket immuno- 
electrophoresis.
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3.2.3 Protein characterisation
3.2.3.1 Rocket immuno-electrophoresis
Single dimension rocket immuno-electrophoresis was performed as described 
previously (Weeke, 1973). A solution consisting of 1% (w/v) ultra-pure agarose in 
0.0315M sodium barbital, 0.0057M diethyl barbituric acid, 0.187M Tris, 0.375M 
glycine, 0.005M sodium azide, pH8.6 was heated in a microwave until totally melted. 
This was then cooled until the temperature reached approximately 56°C and the 
required polyclonal antibody added to a final concentration of 0.4% (w/v). Nine 
millimetres of this solution was rapidly poured onto a level 8 x 9  cm gel-bond plate 
and allowed to set. Once thoroughly set, a line of 2 mm diameter holes 0.5 cm apart 
were punched 1 cm from, and parallel to, the edge of the gel. The gels were then 
stored covered in cellulose film at 4°C until required. Rocket electrophoresis was 
carried out on an LKB Multiphor Electrophoresis Unit. Five microlitres of the sample 
of interest was loaded into each well of the rocket gel. The rocket gel was then placed 
on the cooling block of the electrophoresis chamber and lint wicks soaked in buffer 
were placed at each edge of the gel to act as charge carrying bridges between the 
reservoir tanks and the gel. Rocket gels were run at a current of 70 mA for 60 to 80 
minutes after which the plate was squash blotted to facilitate drying. This was 
performed by placing 1 sheet o f blotting paper over the gel and overlaying it with 
absorbent paper towels, a glass plate and a heavy lead weight. Pressure was applied 
for 15-20 minutes after which the gel was dried under a hair dryer and the ‘rockets’ 
visualised by staining with Coomassie brilliant blue and then destained (figure 3.4).
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Figure 3.4: Rocket gel run at 70V for 2 hours, Lane 1, positive control 
(1.58mg/ml) Lane2, recombinant wildtype a , - antitrypsin. Lane 3, recombinant 
Asn 314 Ala/Lys328 Ala a , - antitrypsin. Lane 4, negative control. Lane5, 
recombinant Asn 314 Ala a , - antitrypsin.
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3.2.3.2 Polyacrylamide gel electrophoresis (PAGE)
The protein samples were confirmed as being homogeneous, monomeric op- 
antitrypsin by SDS and non-denaturing PAGE (Appendix VI).
3.2.3.3 Transverse urea gradient gels (TUG)
Transverse urea gradient gels were carried out using a similar procedure to that of 
Goldenberg (Goldenberg, 1989). Gels were essentially the same composition as non­
denaturing gels consisting o f 7% (w/v) polyacrylamide with a 0 to 8M urea transverse 
linear gradient.
0M urea 8M urea
Non-denaturing PAGE separation buffer 3mL 3mL
Acrylamide 2.8mL 2.8mL
Urea 0g 5.76g
Water 6.2mL to 12mL
TEMED 1 2 p,l 1 2  pi
10% (w/v) AMPS added as described in text
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The gradient was achieved by pouring the urea gradient (3.45mL of OM urea mixing 
into 3.45mL of 8M urea gel mix with 20pl of freshly prepared 10% AMPS added to 
each well immediately before pouring) with the glass plates at 90° (sealed sides and 
bottom with 1 % agarose gel), then rotating back through 90° and pouring the stacker 
(1,5mL of non-denaturing PAGE stacking gel mix with 20 pi of freshly prepared 10% 
AMPS added). The glass plates were specially cut as 100 x 100 mm squares, with a 
central 10  x 80 mm section cut out of the top (by final orientation) of one plate to 
create ears (figure 3.5).
Protein samples of 150pg (for Coomassie-stained gels) or 20|ig (for sliver-stained 
gels) were prepared by addition of an appropriate volume of 5x non-denaturing PAGE 
loading buffer and loaded in a well across the length of the stacking gel. The gels 
were run using non-denaturing PAGE discontinuous buffers in specially constructed 
gel tanks, at a constant current of 25mA, and fan-cooled, until the loading buffer dye 
front reached the bottom of the gel. Proteins were visualised by staining with 
Coomassie Blue and destaining or by silver staining.
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F igu re  3.5: Diagram showing orientation of TUG gel plate
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3.2.4 Active site titration
Active site titration’s of ai-antitrypsin were performed by incubating the increasing 
concentrations of the inhibitor with bovine chymotrypsin of known active site (Kezdy, 
1970). Recombinant wildtype and mutant ai-antitrypsin was diluted from stock in 
reaction buffer (0.03M sodium phosphate, 0.16MNaCl and 0.1% (w/v) PEG 4000, pH 
7.4), to give an initial solution estimated to have an active site concentration of 0.1 p.M. 
Increasing amounts of a  i-antitrypsin (0-5pmol of estimated active site) were mixed 
with 5pmol of bovine chymotrypsin in reaction buffer, in a total volume of 1 OOpl. The 
mixture was incubated for 10 minutes ( »  5 x X\a), according to previous calculations 
of association kinetics (Lomas, 1995), at room temperature and the residual proteolytic 
activity was determined by adding 900pl of reaction buffer containing the substrate 
succinyl-L-alanyl-L-alanyl-prolyl-L-phenylanalyl-p-nitroanilide (Succ-Ala-Ala-Pro- 
Phe-pNa) at a concentration of 0.16mM. The change in OD405 over 3 minutes was 
observed. Active site values were obtained by plotting residual proteolytic activity 
against the amount of inhibitor and extrapolating to the x-intercept (Beatty et al., 
1980). This value gives the amount o f total a  i-antitrypsin required to inhibit 5pmols 
of bovine chymotrypsin. Since inhibition is effectively irreversible in these conditions 
and requires 1 : 1  stoichiometry of enzyme: inhibitor active site, the specific activity of 
the sample is defined as:
______5 x HP12___________ x ______ molecular mass of inhibitor
value at intercept of x-axis concentration of inhibitor in initial solution
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3.2.5 SDS-PAGE assessment of the stability of the serpin-proteinase complex
Wildtype or mutant recombinant ai-antitrypsin was incubated with varying molar 
ratios o f human neutrophil elastase or trypsin at 37°C for up to 13 days. Aliquots were 
withdrawn at different time points, heated at 98°C for 5 minutes and then snap frozen 
and stored at -70°C until required. The stability of the serpin-proteinase complex was 
assessed by SDS-PAGE with the intensity of the bands being determined by 
densitometry.
3.2.6 Kinetic assessment of the stability of the serpin-proteinase complex
Complexes were prepared by incubating 4pM ai-antitrypsin with trypsin in a 9:1 
molar ratio in 50mM Tris, 0.15M NaCl, pH 7.4 for 60 minutes at room temperature. 
They were dissociated by 200-fold dilution into 0.3mM substrate (S2222) at 20 or 
37°C. This quantity of substrate prevented any released enzyme re-associating with 
the inhibitor. Complex dissociation was monitored continuously for 60 minutes by 
measuring the generation of p-nitroanilide at OD405. Under these conditions, less than 
5% of the substrate was converted to product and less than 3% of the complex 
dissociated. Thus the data from the initial linear rate of complex dissociation could be 
fitted to the equation proposed by Jesty, 1979.
At = Ao + V0t + K0ff x [E-I]o x TN x t2/2
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Where At and A0 are the absorbance at time t and 0 respectively, V0 is the rate of 
change in OD405 at time 0 , k0tr is the first order rate constant for complex dissociation, 
[E-I]o is the starting concentration of complex and TN is the value for hydrolysis of 
substrate by enzyme under the conditions of the experiment, expressed as the rate of 
change in OD405 per unit of enzyme concentration. The coefficients o f the second 
order polynomial equation were fitted parameters and were calculated from the fitted 
coefficient of the t term using the concentration of complex and independently 
measured turnover number. The a  1-antitrypsin that dissociates from the complex is in 
an inactive form. Thus there was no contribution from the inhibitor re-associating 
with enzyme during the experiment.
3.3 Results
The Asn314Ala, Lys328Ala and Asn314Ala/Lys328Ala a  1-antitrypsin mutants 
were prepared to assess the effect of A s314 and Lys328 on the stability of the 
serpin-proteinase complex. The recombinant wildtype and mutant a  1-antitrypsin 
were confirmed to be monomeric on non-denaturing and SDS-PAGE.(figure 3.6). 
When assessed by transverse urea gradient (TUG) PAGE, the recombinant a p  
antitrypsin had an unfolding profile characteristic of a native, metastable serpin 
(figure 3.7) a similar unfolding pattern was observed for the Asn314Ala,
Lys328Ala and Asn314Ala/Lys328Ala a  1-antitrypsin mutants.
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Figure 3.6: 7.5 - 15% SDS - page gel. Lane 1, molecular weight marker. Lane 2, 
cleaved recombinant wildtype a , - antitrypsin. Lane 3, recombinant wildtype a t - 
antitrypsin. Lane 4, recombinant Asn 314 Ala a , - antitrypsin; Lane 5, 
recombinant Lys 32B Ala a , - antitrypsin; Lane 6 , recombinant Asn 314 Ala/Lys 
328 Ala a , - antitrypsin.
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Figure 3.7: 0-8m urea, 7% (w/v acrylamide ) TUG PAGE of recombinant 
wildtype a , - antitrypsin. 20ug of protein was loaded and visualised by 
coomassie blue staining.
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The recombinant wildtype a  i-antitrypsin was 59.67% active as an inhibitor of bovine 
chymotrypsin, while the Asn314Ala mutant was 64.73% active, the Lys328Ala 
67.56% active (figure 3.8) and the double mutant Asn314Ala/Lys328Ala was 63.93% 
active as an inhibitor of bovine chymotrypsin. The susceptibility o f the different 
mutants to cleavage by Papain and V8Protease was identical to that of wildtype oti- 
antitrypsin over a range of concentrations. The thermal stability assay also showed no 
difference between the mutant ai-antitrypsin and the recombinant ai-antitrypsin.
All three mutants had the same stoichiometry of inhibition and a similar association 
rate constant with trypsin (table 3.1). Wildtype ai-antitrypsin formed SDS-stable 
complexes when incubated with increasing concentrations of both porcine trypsin and 
neutrophil elastase (figure 3.9). The three mutants all formed SDS-stable complexes 
with neutrophil elastase (figures 3.10 and 3.11) and porcine trypsin (figures 3.13 and 
3.14) when assessed by SDS-PAGE but in all cases the complexes dissociated when 
incubated at 37°C for 13 days. This was in contrast to wildtype ai-antitrypsin, which 
formed stable complexes that dissociated only slowly when incubated under identical 
conditions.
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Figure 3.8: Active site titration of recombinant Asn314Ala co-antitrypsin. 0-5pmol of 
initially estimated active site of co-antitrypsin was reacted in lOOpl reaction volume 
with 5pmol bovine chymotrypsin. The reaction was incubated at room temperature for 
10 minutes ( »  5 x ti/2) and residual proteinase activity was then assessed by adding 
the substrate Succ-A-A-P-F-pNA.
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Table 3.1: The second order rate constants (kass) of ai-antitrypsin mutants with 
porcine trypsin and the dissociation rate constants (kdjss) of complexes with porcine 
trypsin at 20 and 37°C.
Wildtype Asn314Ala Lys328Ala Asn314Ala/
Lys328Ala
Porcine trypsin 6 .14+/-0.53xl04 6.26+/-0.48xl04 6.19+/-0.58xl04 6.35+/-0.20xl04
kass (M 'V 1,20°C)
Porcine trypsin 5.71±0.51xl0"8 2.90+0.52x1 O'7 6.02±1.08xl0'7 1,63±0.36xl0'6
kdiss (s'1, 20°C)
Half-life (days) 140 28 13 5
Porcine trypsin 1.63+0.10x1 O'7 1.30+0.1 lxlO'6 2.43±0.14xl0‘6 3.79+0.16xl0'6
kdiss (s'1, 37°C)
Half-life (days) 49 6 3 2
The results are the mean and standard error of 3 independent experiments. The half- 
life of the a  i-antitrypsin-trypsin complexes is shown.
I l l
Analysis o f the gels showed that the Asn314Ala and Lys328Ala ai-antitrypsin had 
similar effects on complex formation with neutrophil elastase but combining the 
mutants in Asn314Ala/Lys328Ala ai-antitrypsin increased the instability of the 
complex (figure 3.11). No proteinase inhibitor such as aprotinin was added to these 
reaction mixtures and thus the dissociation of the Asn314Ala/Lys328Ala a i- 
antitrypsin/neutrophil elastase complex was visualised as a loss of the high molecular 
mass complex band accompanied by an increase in cleaved ai-antitrypsin.
The significance o f the Asn314 and Lys328 residues was underscored by assessing the 
interaction with porcine trypsin. Once again wildtype, Asn314Ala, Lys328Ala and 
Ans314Ala/Lys328Ala ai-antitrypsin all formed an initial complex with trypsin that 
was stable on SDS-PAGE (figure 3.12, 3.13 and 3.14). Asn314Ala and Lys328Ala 
ai-antitrypsin (figure 3.13) both caused a reduction in stability o f the inhibitory 
complex which was most marked with the double mutant, Asn314Ala/Lys3 2 8Ala a  i - 
antitrypsin (figure 3.13). The serine proteinase inhibitor aprotinin was added to these 
reactions in 100 fold molar excess after complex formation. Thus the released trypsin 
from complex dissociation was unable to attack and cleave the residual native a j- 
antitrypsin. In these experiments the stability of the complex was assessed by the loss 
of the high molecular mass complex band on SDS-PAGE and an increase in free 
proteinase.
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Figure 3.9: 12% w/v SDS-PAGE to assess the stability of complexes of a  i-antitrypsin 
with human neutrophil elastase and trypsin. Wildtype, Asn314Ala, Lys328A!a and 
Asn314Ala/Lys328Ala cti-antitrypsin were added to human neutrophil elastase and 
porcine trypsin at varying molar ratios and then incubated at 37°C before being 
assessed by gel electrophoresis. Cpx indicates the ot]-antitrypsin-proteinase complex, 
c-cpx is cleaved complex, intact AT is monomeric unreacted oti-antitrypsin, c-AT is 
reactive loop cleaved ai-antitrypsin and protease is unreacted or dissociated enzyme. 
Lanel, molecular mass markers (78, 66, 45 and 30 kDa); lane2, wildtype cti- 
antitrypsin; lanes 3-6, wildtype oti-antitrypsin:trypsin at 1:0.25, 1:0.5, 1:1 and 1:2 
molar ratios respectively; lane 7, porcine trypsin; lane 8, wildtype a.)-antitrypsin; lane 
9-12, wildtype ai-antitrypsin-neutrophil elastase at 1:0.25, 1:0.5, 1:1 and 1:2 molar 
ratios respectively; lane 13, neutrophil elastase.
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Figure 3.10: Assessment o f complex formation of wildtype a r antitrypsin with human 
neutrophil elastase. oti-Antitrypsin was incubated in 4:1 molar ratio with neutrophil 
elastase at 37°C and aliquots were removed at the times shown. Lane 1, molecular 
mass markers (78, 66, 45 and 30 kDa); lane 2, a.r antitrypsin; lane 3, a r antitrypsin- 
neutrophil elastase complex at 30 minutes; lane 4-9, ai-antitrypsin-neutrophil elastase 
complex at 1, 2, 3, 4, 5 and 6 days respectively; lane 10, neutrophil elastase.
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Figure 3.11: Assessment of complex formation of Asn314Ala/Lys328Ala gcj- 
antitrypsin with human neutrophil elastase. ai-Antitrypsin was incubated in 4:1 molar 
ratio with neutrophil elastase at 37°C and aliquots were removed at the times shown. 
Lane 1, molecular mass markers (78, 66, 45 and 30 IcDa); lane 2, a.)-antitrypsin; lane 
3, ai-antitrypsin-neutrophil elastase complex at 30 minutes; lane 4-9, ai-antitrypsin- 
neutrophil elastase complex at 1, 2, 3, 4, 5 and 6 days respectively; lane 10, neutrophil 
elastase.
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Figure 3.12: Assessment o f complex formation of wildtype a.i-antitrypsin with porcine 
trypsin. ai-Antitrypsin was incubated in 4:1 molar ratio with porcine trypsin at 37°C 
and aliquots were removed at the times shown. Aprotonin was added to a final 
concentration of 1 mg/ml after the 30 minute time point. Lane 1, a.i-antitrypsin; lane 
2, aj-antitrypsin-porcine trypsin complex at 30 minutes; lane 3-9, ai-antitrypsin- 
porcine trypsin complex at 1,3, 5, 7, 9, 11 and 13 days respectively; lane 10, porcine 
trypsin.
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Figure 3.13: Assessment of complex formation of Lys328Ala a ,-antitrypsin with 
porcine trypsin. a r  Antitrypsin was incubated in 4:1 molar ratio with porcine trypsin 
at 37°C and aliquots were removed at the times shown. Aprotonin was added to a final 
concentration of 1 mg/ml after the 30 minute time point. Lane 1, ai-antitrypsin; lane 
2, ai-antitrypsin-porcine trypsin complex at 30 minutes; lane 3-9, ai-antitrypsin- 
porcine trypsin complex at 1, 3, 5, 7, 9, 11 and 13 days respectively; lane 10, porcine 
trypsin.
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Figure 3.14: Assessment of complex formation of Asn314Ala/Lys328Ala a .r  
antitrypsin with porcine trypsin. a r  Antitrypsin was incubated in 4:1 molar ratio with 
porcine trypsin at 37°C and aliquots were removed at the times shown. Aprotonin was 
added to a final concentration of 1 mg/ml after the 30 minute time point. Lane 1, a.i- 
antitrypsin; lane 2, a.i-antitrypsin-porcine trypsin complex at 30 minutes; lane 3-9, a r  
antitrypsin-porcine trypsin complex at 1, 3, 5, 7, 9, 11 and 13 days respectively; lane 
10, porcine trypsin.
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The dissociation rate constant for the inhibitory complexes with trypsin was 
determined by kinetic analysis at 20 and 37°C (table 3.1 and figure 3.15). Asn314Ala 
and Lys328Ala a r antitrypsin both destabilised the inhibitory complex with trypsin 
and increased that rate of complex dissociation at 20°C. When mutations were 
combined there was an additive effect with Asn314Ala/Lys328Ala ai-antitrypsin 
having a dissociation rate constant 29 fold greater than the wildtype protein. The 
effect of the mutants on the stability of the complex was exacerbated by raising the 
temperature o f the reaction mix to 37°C. This increased the dissociation rate constant 
of all 3 mutants with trypsin but also increased the dissociation rate constant of the 
wildtype protein.
The dissociation rate constant of Asn314Ala/Lys328Ala ai-antitrypsin was 23 fold 
greater than that of the wildtype protein at this temperature (37°C). Once again the 
effect of Asn314Ala and Lys328Ala cti-antitrypsin was additive indicating that both 
the Asn314 and Lys328 residues independently play an important role in stabilising 
the complex. The significance of these data was illustrated by considering the half-life 
of the inhibitory complexes (table 3.1).
The Asn314Ala/Lys328Ala mutant reduced the half-life of the a  i -antitrypsin-trypsin 
complex from 140 days to 5 days at 20°C and from 49 days to 2 days at 37°C. The 
dissociation rate constants of complexes with human neutrophil elastase were not 
determined as the Km of the substrate was too high.
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Figure 3.15: Kinetic assessment of complex dissociation. Complexes of a ,- 
antitrypsin and trypsin were prepared by incubating 2nM of enzyme with a 9 fold 
molar excess of op -antitrypsin at room temperature. They were dissociated by 200- 
fold dilution into 0.3mM substrate (S2222) AT 37°C. Inverted triangle, wildtype cc,- 
antitrypsin; filled circle, Asn314Ala a,-antitrypsin; cross Lys328AIa a,-antitrypsin; 
open circle, Asn314Ala/Lys328Ala co-antitrypsin.
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3.4 Discussion
Lys328 and Asn314 are not widely conserved in the serpin superfamily (Whistock, 
1996). However, these stabilising serpin-proteinase interface interactions are also 
likely to be important in other pairs of serpins and proteinases. Examination of the 
cleaved structures of oti-antitrypsin (Loebermann et al., 1984), aj-antichymotrypsin 
(Baumann, et al., 1991), antithrombin (Delarue et al., 1990), plasminogen activator 
inhibitor-1 (Aertgeerts et al., 1995) and horse leucocyte elastase inhibitor (Baumann et 
al., 1992), showed that a residue that corresponds to position 328 or 314 in a i- 
antitrypsin is available to hydrogen bond with the proteinase.
The amide side chain of Asn314 of a  i-antitrypsin forms hydrogen bonds with the main 
chain carbonyl oxygen’s of Ser214, Trp215 and 194Asp in the proteinase (Huntington 
et al., 2000). Lys328 forms a salt bridge with Aspl94. In ai-antichymotrypsin the 
328 position is filled by an Ala residue that cannot form hydrogen bonds. However, 
the 314 position is occupied by a Ser that can hydrogen bond to the main chain 
carbonyl oxygen’s of Ser214, Trp215 and 194Asp in the proteinase. In antithrombin 
the 328 position is occupied by 364Tyr that can hydrogen bond to 194Asp in the 
proteinase. The 314 position is filled by 347Pro, which would be unable to stabilise 
the inhibitory complex.
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In horse leucocyte elastase inhibitor the 328 position is filled with a phenylalanine but 
the 314 position contains an arginine, which can readily substitute for the interactions 
at the 328 site. Finally plasminogen activator inhibitor-1 has 334His in the 328 
position and 319Gln in the 314 position. Both can provide hydrogen bonds to stabilise 
the target proteinase. Taken together these observations underscore the importance of 
the residues that occupy positions 328 and 314 in ai-antitrypsin and imply that this 
interaction may be a general mechanism in stabilisation o f the serpin-proteinase 
complex.
The demonstration of an interaction that stabilises the serpin-proteinase inhibitory 
complex confirms that the enzyme must be fixed at the distal pole o f the serpin in the 
final inhibitory complex (figure 3.1). This is in keeping with biophysical analysis 
(Stratikos & Gettins, 1997; Stratikos & Gettins, 1998; Wilczynska et al., 1997) and 
the recent crystal structure of the complex (Huntington etal., 2000). It strongly argues 
against the suggestion that in the final complex the proteinase oscillates between 2 
positions characterised by partial and full loop insertion of the inhibitor (O’Malley & 
Cooperman, 2001).
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CHAPTER 4
MAJOR FINDINGS AND CONCLUSIONS
4.1 The Role of Alpha-1-Proteinase Inhibitor in Asthma
The finding of functionally abnormal ai-AT in asthmatic patients may be of 
considerable importance in light of the fact that asthma has been recognised as an 
inflammatory disorder. In-addition to a novel polymorphism we identified 2 new 
variants of ai-AT in association with asthma. Although these new variants were not 
related to a deficiency state, they demonstrate the extent and complexity of genetic 
susceptibility to atopic asthma. Knowledge of the molecular basis of variants and 
polymorphisms, both normal and pathogenic, can be useful for the identification of the 
residues most important for protein function.
4.2 Stabilisation of the serpin-proteinase complex through conserved 
interactions
Making use of the recently described serpin-proteinase complex crystal structure and 
site directed mutagenesis we have demonstrated residues in alpha-1 antitrypsin that are 
important in stabilising the final serpin-proteinase complex. Structural homology 
suggests that this interaction is likely to be important in stabilising the inhibitory 
complex in other serpin-proteinase pairs.
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Appendix I
PCR Protocol
Materials:
The Taq DNA polymerase and the dNTPs were from Promega (Madison, WI); the 
primers used were synthesised by Genosys Biotechnologies Inc (Woodlands, TX); the 
sterile mineral oil was supplied by Sigma Chemical Co (St Louis, MO); the sterile 
double-distilled water was supplied by SABAX (Johannesburg); the filtered pipette 
tips and the 0.5 mL PCR tubes were from Laboratory and Scientific Equipment Co 
(Johannesburg); all other reagents were of analytical grade (Merck, Darmstadt,
Germany). 
Reagent buffer
1.5 mM MgCl2 0.031 g
10 mM Tris base 0.121 g
50 mM KC1 0.355 g
Dissolve in 95 mL of double-distilled water (ddH20), adjust the pH to 8.3 with HC1 
and adjust the volume to 100 mL with ddH20 . Autoclave and store at 4°C, or aliquot 
and store at -20 °C (long-term storage).
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The work in this project has used molecular and structural biology to understand 
clinical conditions. It has also continued the trend of providing insights into protein 
structure and conformational transitions by the study of clinically relevant pathological 
mutants and protein-protein interactions. Such dialogue between the clinical and the 
structural will help our understanding of the genetic data amassing on associations 
between genetic polymorphisms and disease.
It will be particularly important in understanding conditions that can be classed as 
conformational diseases. Moreover it is an approach that is vital to achieving the goal 
of designing and targeting therapeutic agents capable of modulating pathological 
transitions.
124
Standard PCR protocol
The following was the standard PCR protocol used in this study, with modifications as 
described in the relevant chapters.
To a 0.5 mL PCR tube, the following reagents were added:
25 pL reagent buffer 
10 pL dNTP mix
1 pL (typically 100 pmol) each appropriate primer 
20-25 pL (~1 pg) DNA
Each sample was overlaid with 50 pL of lightweight mineral oil and the tubes were 
placed in a Hybaid DNA thermal cycler. Following the “hot start” and the subsequent 
reduction of the sample temperature to the appropriate annealing temperature, 2 units 
of Taq DNA polymerase were added to each sample. The samples were then 
processed as described in the relevant chapters.
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APPENDIX II
Agarose gel electrophoresis
Electrophoresis through agarose gels is the standard method used to separate, identify 
and purify DNA fragments (Maniatis et al., 1985). The technique is rapid, simple and 
resolves mixtures of DNA fragments that cannot be separated efficiently by other 
sizing procedures. The technique is based on the principle that negatively charged 
DNA fragments migrate toward a positive pole at different rates, depending on the 
following parameters:
(a) the molecular size of the DNA-linear duplex DNA molecules migrate in an end-on 
position through the gel matrix at rates that are inversely proportional to the logio of 
their molecular weights (Maniatis et al., 1982; Stine, 1989).
(b) the agarose concentration - a DNA fragment of a particular size migrates at 
different rates through gels containing different agarose concentrations. The 
relationship between the logarithm of the electrophoretic mobility of DNA (pg) and 
the gel concentration (x) is linear, and is described by the following equation:
log|i = logMo - KrT,
where po is the free electrophoretic mobility and Kr is the retardation co-efficient, a 
constant that is related to the gel properties and the size and conformation of the 
migrating DNA molecules (Maniatis et al., 1982).
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(c) the applied current - at low voltages, linear DNA molecules migrate at a rate that is 
proportional to the applied voltage. As the strength of the electric field increases, the 
mobility o f the high molecular weight DNA fragments increases differentially. 
Consequently, the effective separation range of agarose gels decreases as the voltage is 
increased-maximum resolution of DNA is obtained by running gels at no more than 5 
V/cm (Maniatis et al., 1982; Brown, 1989).
(d) base composition and temperature - the base composition of the DNA and the gel 
temperature during electrophoresis do not affect DNA migration through the gel 
significantly, which means that the relative electrophoretic mobilities of DNA 
molecules o f different sizes do not change between 4°C and 30°C (Maniatis et al., 
1982).
The location o f DNA within the gel can be determined directly by staining the DNA in 
the gel with a fluorescent, intercalating dye such as ethidium bromide (EtBr); as little 
as 1 ng of DNA can be detected by direct examination of the gel upon ultraviolet (UV) 
illumination (Maniatis et al., 1982), typically at a wavelength of 302nm. Ethidium 
bromide is a phenanthridine derivative and contains a planar group that intercalates 
between the stacked bases of DNA (Williams, 1989). The fixed position of the planar 
group and its proximity to the bases causes dye that is bound to DNA to fluoresce at a 
greater intensity than dye that is in free solution (Williams, 1989). UV irradiation 
absorbed by the DNA at 260nm and transmitted to the dye, or irradiation that is 
absorbed at 300nm and 360nm by the bound dye, is emitted at 590nm in the red- 
orange region o f the visible spectrum (Maniatis et al., 1982; Stine, 1989).
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Materials:
The agarose and low melting temperature agarose were supplied by Promega 
(Madison, WI); the Ficoll (Type 400) was from Sigma Chemical Co. (St Louis, MO); 
the sterile distilled water was from SAB AX (Johannesburg); all other reagents were of 
analytical grade (Merck, Darmstadt, Germany).
Gel concentration Agarose (g) 5xTBE, pH8.2 dLLO (mL)
(%) (mL)
0.7 0.20 5 25
1 0.33 5 25
2 0.67 10 25
4 3:1* 10 90
*3 g agarose:! g low melting temperature agarose
1. Add buffer at room temperature to a beaker that is 3-4 times the volume of the final 
solution.
2. Sprinkle agarose powder into the soLution while it is being stirred in order to 
prevent the formation of lumps.
3. Boil the slurry in a microwave oven (100% power, 2-4 min), stirring at intervals, to 
liquefy the agarose.
4. After agarose is dissolved, cool to 50°C (higher for the 4% gels) add 1.5 pL/30 mL 
or 5-10 pL/100 mL EtBr (from a 10 mg/mL stock solution) to a final concentration of
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0.5 pg/mL and pour the solution into a clean, sealed gel cassette with the comb in 
place (there should be a space of 0.5-1.0 mm between the bottom of the teeth and the 
base of the cassette, so that the sample wells are sealed).
5. After the gel sets at room temperature for 30 min, over with a 2-3 mm layer of 
running buffer and refrigerate for another 30 min.
6. Mix 10 pL of each PCR reaction with 8 pL of a 6x loading dye and load 15 pL of 
this mixture per well.
7. Run at 4.5 V/cm (for a gel of 12.5x20 cm) or 8.8 V/cm (for a gel of 5.5x9 cm); for 
the purposes of the present study, all agarose gels were run at 80 V in 0.5XTBE buffer 
for 45 min, (1% and 2% gels) and 114 hour (3% and 4% gels).
Electrophoresis buffers
Buffer
Tris-acetate EDTA (TAE)
Tris-borate EDTA (TBE)
Working solution (lx)
0.04 M Tris-acetate 
0.002 M EDTA
0.089 M Tris-borate 
0.002 M EDTA
Concentrated stock 
(per litre)
50x
242 g Tris base
57.1 mL glacial acetic
acid
100 mL 0.5 M EDTA, 
pH 8.0
lOx
108 g Tris base 
55 g boric acid 
40 mL 0.5 M EDTA, 
pH 8.0
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6x Gel loading dye
bromophenol blue 0.25 g
xylene cyanol FF 0.25 g
Ficoll Type 400 15.00 g
Dissolve in lOOmL sterile water, aliquot and store at 4°C.
132
APPENDIX III
Direct sequencing of PCR products
The most commonly use method for DNA sequencing is the chain termination method 
developed by Sanger et al. (1977). This method involves the in vitro synthesis of a 
DNA strand by a polymerase, using a single-stranded DNA template (Sanger et al., 
1977), with modern methods, double-stranded PCR products can be sequenced 
directly. Synthesis is only initiated at the site at which a primer binds to the template 
and the synthesis is terminated upon the incorporation of a nucleotide analogue that 
does not allow continued DNA strand elongation (Sanger et al., 1977; Sanger et al., 
1982; Brown, 1989). These nucleotide analogues are 2',3'-dideoxynucleoside 5'- 
triphospates (ddNTPs) which lack the 3'-OH (hydroxyl) group that is essential for 
polymerase recognition and strand elongation, so that termination occurs specifically 
at places where the deoxynucleotide should be incorporated (Sanger et al., 1977; 
Sanger et al., 1982). Therefore, if  a primer is incubated with a template with a DNA 
polymerase in the presence of a mixture o f a ddNTP and the four dNTPs (one of which 
is radioactively labelled), a mixture of fragments all having the same 5' end and 
ddNTP residues at their 3' ends is obtained (Sanger et al., 1977; Sanger et al., 1982).
When using direct sequencing, most of the dNTPs and primers used during the PCR 
remain intact and will interfere with normal sequencing methods, which also utilise 
primers and nucleotides. Two hydrolytic enzymes, shrimp alkaline phosphatase (SAP) 
and exonuclease I (exo I) can be used to remove the unwanted molecules. The 
exonuclease I removes residual single-stranded (ss) primers and any ssDNA produced
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by the PCR, while the SAP removes remaining dNTPs from the PCR, which would 
affect the labelling step of the sequencing reaction. It is essential that high quality and 
good yield PCR is performed in order to obtain high quality sequence information.
Materials:
The Thermo Sequenase radiolabelled terminator cycle sequencing kit, the shrimp 
alkaline phosphatase, the exonuclease and the 20x glycerol tolerant buffer (GTB) were 
obtained from Amersham Life Science Inc. (Cleveland, Ohio); the acrylamide and the 
urea were from Promega (Madison, WI); the ammonium persulfate, bis-acrylamide 
and TEMED were supplied by BioRad (Hercules, CA); the Sigmacote was from 
Sigma Chemical Co. (St. Louis, MO); the 0.5 mL microcentrifuge tubes were supplied 
by Laboratory and Scientific Equipment Co. (Johannesburg); the sterile double- 
distilled water was from SABAX (Johannesburg); the 3 MM Whatman filter paper 
was from Whatman International (England).
Sequencing protocol
1. Template preparation
To a 0.5 mL microcentrifuge tube add:
5 pL (0.5 pmol) PCR amplification mixture 
1 pL (1.0 U/pL) Exonuclease I (exo I)
1 pL (2.0 U/pL) Shrimp alkaline phosphatase (SAP)
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Spin the samples briefly to collect all the reagents at the bottom of the vial and 
incubate at 37°C for 15 min and inactivate the exo I and SAP by heating to 80°C for 
15 min (performed in a Hybaid DNA thermal cycler).
2. Termination mixes
Prepare the termination mixes on ice. Mix 2 pL of nucleotide master mix (dGTP) and 
0.5 pL of [a-33P] ddNTP (G, A, T, or C - one of each per sequence) to produce a 
termination mix for each ddNTP. Label, fill and cap four tubes (‘G’, ‘A ’, ‘T \  ‘C’) 
with 2.5 pL of each termination mix. To prepare termination mixes for (n) 
reactions, mix:
G A T C
Nucleotide master mix (pL) (2 x n) (2 x n) . (2 x n) (2 x n)
[a-33P] ddNTP (pL) (0.5 x n) (0.5 x n) (0.5 x n) (0.5x n)
Total (pL) (2.5 x n) (2.5 x n) (2.5 x n) (2.5xn)
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3. Reaction mixture
For multiple (n) reactions with different primers and/or templates, prepare a n+1 batch 
o f reaction buffer, water, polymerase and aliquot; then add the unique primer and/or 
template in the appropriate concentration and volume to the aliquots.
Reaction buffer 2 pL
DNA _ pL (50-500 ng)
Primer _ pL (0.5-2.5 pmol) o f each primer
H20 _ pL (to adjust total volume to 20 pL)
Thermo Sequenase polymerase (4U/pl) 2 pL (8 units polymerase-add last)
Total 20 pL
4. Cycling termination reactions
Transfer 4.5 pL o f reaction mixture (prepared in step 3) to each termination tube 
(‘G’, ‘A ’, ‘C \  ‘T ’) from step 2. Mix well and overlay with 10-20 pL of mineral oil (if 
needed). Cap and place the tube in the thermal cycler (Flybaid DNA thermal cycler). 
The following cycling parameters were used: 95°C for 1 min, 55°C for 1 min and 72°C 
for 2 min for a total of 30 cycles.
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5. Termination reaction
Add 4 pL of stop solution to each of the termination reactions, mix thoroughly and 
centrifuge briefly to separate the oil from the aqueous phase. Alternatively, remove 6 
pL from each termination reaction and transfer to a fresh tube containing 3-4 pL of 
stop solution. Samples may be stored frozen until ready to load the sequencing gel. 
Immediately before loading, heat samples to 90°C for 10 min and load 3 pL/lane (all 
the samples should be loaded onto the gel within 5 min).
Plate pretreatment
The plates should be cleaned thoroughly with absolute ethanol and allowed to dry, 
following which the smaller of the two plates (i.e. the notched plate) should be 
siliconised (Sigmacote was used for the present study). The spacers are then placed 
along the edge of the large plate and the notched plate is then placed on top, such that 
all the edges are even. The plates are then taped together, taping the bottom 
edge last.
Gel preparation
Gel concentration Acrylamide/ Urea 20x glycerol tolerant ddH20
(%) bis-acrylamide (7 M) gel buffer (GTB)
8 7.2 g/0.8 g 42 g 4-5 mL* ~45 mL
*use 4 mL for faster gel migration.
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Dissolve the above reagents, adjust the volume to 100 mL with ddH20 , filter at 4°C 
(the colder the gel solution, the easier it is to pour) and degas for 3 min. When ready 
to pour, add 1 mL of 10% ammonium persulfate and 25 pL TEMED. Gels should be 
prepared 2-20 hrs prior to use (if kept overnight, store covered at 4°C).
The gels were pre-run at 90 W constant power for 30 min, until the gel temperature 
reached 48-50°C. Samples were then loaded and the gels were run for 1 'A-3 hrs at 
room temperature at 60 W (constant power) or until the bromophenol blue dye front 
reached the bottom of the gel. The gel temperature was maintained at 48-50°C. The 
running buffer used was 0.5xGTB. After electrophoresis, the gels were blotted onto 3 
MM Whatman filter paper, dried on a slab gel dryer at 80°C for 1-1‘A hrs and 
autoradiographed for 24-72 hrs (depending on the age of the [a-33P] ddNTP).
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Appendix IV
Automated sequencing of PCR products using the ABI Prism® BigDye™ 
terminator cycle sequencing ready reaction kit
The reaction kit was obtained from PE Biosystems (Cheshire, UK) and in the ready 
reaction format, the dye terminators, deoxynucleotide triphosphates, AmpliTaq DNA 
polymerase, magnesium chloride and buffer are premixed into a single tube of Ready 
Reaction Mix and are ready to use. These reagents are suitable for performing 
fluorescence-based cycle sequencing reactions on single-stranded or double-stranded 
DNA templates, on polymerase chain reaction (PCR) fragments, and on large 
templates, e.g. BAC clones. The dNTP mix includes dITP in place of dGTP to 
minimise band compressions. The dNTP mix also uses dUTP in place of dTTP. 
dUTP improves the incorporation of the T terminator and results in a better T pattern.
The kit contains the sequencing enzyme AmpliTaq DNA polymerase, FS. This 
enzyme is a variant o f Thermus aquaticus DNA polymerase that contains a point 
mutation in the active site. This results in less discrimination against 
dideoxynucleotides. This enzyme also has a second mutation in the amino terminal 
domain that virtually eliminates the 5'->3' nuclease activity of AmpliTaq DNA 
polymerase. The enzyme has been formulated with a thermally stable inorganic 
pyrophosphatase to eliminate problems associated with pyrophosphorolysis.
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Cycle sequencing protocols that rely on the use of AmpliTaq DNA polymerase, FS
offer the following advantages over traditional sequencing methods:
(a) Less hands-on operation.
(b) No alkaline denaturation step required for double stranded DNA.
(c) Same protocol for both single- and double-stranded DNA.
(d) Less starting template needed.
(e) More reproducible results.
PE Biosystems has developed a set of dye terminators labeled with novel, high- 
sensitivity dyes. The dye structures contain a fluorescein donor dye linked to a 
dichlororhodamine (dRhodamine) acceptor dye. The excitation maximum of each dye 
label is that o f the fluorescein donor, and the emission spectrum is that of the 
dRhodamine acceptor. The BigDye terminators are labeled with the following 
dRhodamine acceptor dyes:
Terminator Acceptor Dye Colour of Raw Data on ABI Prism 310 
Electropherograms
A dR6G Green
C DROX Red
G dRllO Blue
T dTAMRA Black
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For optimum results, purify the PCR product before sequencing. In general, any 
method that removes dNTPs and primers should work. The recommended method is 
the use o f the QIAquick™ PCR Purification Kit (an alternative is Shrimp Alkaline 
Phosphatase and Exonuclease I, but this is not as effective).
1) PCR
2) Cleaning of PCR products
3) Cycle Sequencing
i) For each PCR product add the following reagents to a separate tube:
1.0 pL Big Dye™
1.5 pL 5x Big Dye Diluent
0.5 pL Primer (10-20 pmols/pL)
3.5 pL Cleaned PCR product
3.5 pL ddH20
ii) Mix well and spin briefly.
iii) Place tubes in a thermal cycler. Repeat the following for 25 cycles:
96°C for 10 seconds 
50°C for 5 seconds 
60°C for 4 minutes 
Hold at 4°C until ready to purify.
iv) Spin down the contents of the tube in a microcentrifuge.
4) Purifying Extension Products
Unincorporated dye terminators must be completely removed before the samples can 
be analysed by electrophoresis. Excess dye terminators in sequencing reactions 
obscure data in the early part of the sequence and can interfere with sequence 
interpretation.
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Ethanol/Sodium acetate Precipitation:
i) For each sequencing reaction, prepare a 1.5 mL microcentrifuge tube 
containing the following:
2.0 pL of 3M sodium acetate (NaOAc), pH 4.6
50.0 pL of 95% ethanol (EtOH)
ii) Add 10.0 pL ddH20  to the extension reaction tube to make a working volume 
of 20.0 pL.
iii) Pipette the entire contents (20.0 pL) of each extension reaction into a tube of 
sodium acetate/ethanol mixture. Mix thoroughly.
iv) Vortex the tubes and place on ice for 10 minutes to precipitate the extension 
products.
v) Spin the tubes in a microcentrifuge for 30 minutes at 13 000 g.
vi) Carefully aspirate the supernatant with a pipette and discard.
vii) Rinse the pellet with 250 pL of 70% ethanol. Add carefully. Pellet not 
visible.
viii) Vortex briefly.
ix) Spin for 5 minutes in a microcentrifuge at 13 000 g. Again carefully aspirate 
the supernatant and discard.
x) Dry the pellet on a heating block for 5 minutes at 95°C. Do not over-dry.
142
5) Electrophoresis on the ABI Prism 310
i) Resuspend each sample pellet in 20 pL of Template Suppression Reagent 
(TSR), which is supplied with the polymer.
ii) Vortex and spin the samples.
iii) Heat the samples at 95°C for 2 minutes to denature, then chill on ice.
iv) Vortex and spin the samples again. Place on ice until ready to use.
v) Refer to the ABI Prism 310 Genetic Analyser User’s Manual for guidelines on 
loading the samples.
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Appendix V
Mutagenesis, Expression and Purification of Recombinant ai-antitrypsin
The expression and purification of recombinant proteins facilitates production and 
detailed characterization of virtually any protein. Although a wide variety of 
heterologous expression systems have been developed and are currently used to 
produce recombinant proteins, the purification of the proteins obtained can still be 
problematic. Classical purification procedures can be employed, but in most cases 
recombinant DNA techniques permit the construction of fusion proteins in which 
specific affinity tags are added to the protein sequence of interest; the use o f these 
affinity tags simplifies the purification of the recombinant fusion proteins by 
employing affinity chromatography methods.
We made use o f the QIAexpress® system, which is based on the remarkable selectivity 
and affinity o f QIAGEN’s exclusive, patented nickel-nitrilotriacetic acid (Ni-NTA) 
metal-affinity chromatography matrices for biomolecules that have been tagged with 6 
consecutive histidine residues.
Site-directed mutagenesis
A PCR mutagenesis method was used to introduce mutations into the ai-antitrypsin 
gene between the unique restriction sites Bam HI and Hind III. Complementary 
oligonucleotide primers were designed with the chosen mutation centrally in a
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sequence ~20 bases long as described in chapter 3. They were otherwise identical to 
the wildtype ai-antitrypsin template sequence, they ideally primed from G or C and 
were not prone to forming hairpins or primer dimers. PCR mutagenesis was carried 
out using 2 pL Vent Taq polymerase with 20pL of Vent Taq polymerase buffer, 4 pL 
of each primer (primer containing mutation and the C terminal primer of the PQE31 
vector), 4 pL of wildtype a  i -antitrypsin in PQE31 as a template, 6 pL EI2O and 20 pL 
of mixed dNTP stock. The PCR reactions were performed in a MJ Research PTC-200 
DNA Engine Peltier-cycled PCR block programmed to denature at 95°C for 5 
minutes, and then to cycle 25 times through a denaturing step at 95°C for 45 seconds, 
an annealing step at 50°C for 45 seconds and then an extension step at 72°C for 1 
minute. The mixture then underwent a final extension step at 72°C for 5 minutes. The 
PCR products were cleaned using the QIAgen PCR purification kit. A second PCR 
was performed using the N-terminal primer of the PQE31 vector and the previously 
cleaned PCR product, which was used as the second primer. The reaction contained 
0.5 pL Vent Taq polymerase with 5 pL of Vent Taq polymerase buffer, 2 pL of the N- 
terminal primer, 0.5 pL of wildtype a  1-antitrypsin in PQE31 as a template, 3 pL H20 , 
5 pL of mixed dNTP stock and 34 pL of the previously cleaned PCR product. The 
cycling conditions were identical to that described above. The PCR products were run 
on a 1% (w/v) agarose/TBE gel (1% ethidium bromide) at 90V for 30 minutes. DNA 
was visualised by ultraviolet fluorescence of intercalated ethidium bromide and the 
PCR products were cut out and gel purified using the QIAgen gel extraction kit.
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The cleaned DNA was digested at 37°C with 2 pL of each of the restriction enzymes 
Bam HI and Hind III. PQE31 plasmid containing wildtype ai-antitrypsin was 
similarly digested and the restriction products from both digests were gel purified from 
a 1% (w/v) agarose/TBE/ethidium bromide gel.
The following ligation reactions were then set up:
Control Insert
Vector backbone
(Bam HI/Hind III restricted)
2 pL 2 pL
Bam HI/Hind III restricted 
PCR product
0 pL 6 pL
Water 6 pL 0 pL
T4 Ligase 1 pL 1 pL
T4 DNA Ligase buffer 1 pL 1 pL
Total 10 pL 10 pL
These were incubated at room temperature for 2 hours. 2 pL of the ligation mixture 
was transformed into 50 pL E.coli suspension by electroporation using 2 mm cuvettes. 
These were then transferred to a sterile tube and incubated on a shaker at 37°C for 1 
hour. After an hour 300 pL was plated on agar plates containing lOOmg/mL 
ampicillin and allowed to grow overnight at 37°C. Single colonies were then picked 
and two or three colonies grown up. The DNA was prepared and then sequenced to 
check for the mutation of interest and the integrity of the DNA sequence (Appendix 
IV).
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Preparation of electro-competent E.coli
All procedures involving cells were carried out using a strict sterile technique to 
prevent contamination. Five hundred millilitres of sterile 2xTY was inoculated with a 
loop of non-transformed SG I3009 E.coli from an agar plate or 10 pL from pre­
existing stocks and grown at 37°C until mid log-phase (OD6oo of 0.6-0.8). The flask 
was cooled in iced water and the cells harvested by centrifugation at 4000 ref for 3 
minutes, the cell pellet was then resuspended in 50mL of ice-cold sterile distilled 
water and centrifuged again at 4000 ref for 3 minutes. The cells were resuspended in 
5mL of ice-cold sterile distilled water and once again centrifuged at 4000 ref for 3 
minutes. The cells were then resuspended in lmL of 10% (v/v) ice cold glycerol. 
Aliquots of 50pL were then snap frozen in liquid nitrogen and stored at -70°C.
Electro-transformation
Forty microlitres of electro-competent cells were mixed with 1 to 2 pL of plasmid 
DNA and placed in a 0.2 cm-gap electroporation cuvette, which was inserted into the 
chamber slide of a Gene Pulsar. The electroporation parameters used were: 2.5 KV, 
25 pF and 200 W, which gave a field strength of 12.5 KV/cm and a time constant of
4.2 to 4.8 ms. Immediately after electroporation the cells were resuspended in 1 mL of 
2xTY, transferred into a sterile tube and incubated at 37°C for 30 minutes. One 
hundred microlitres of each 1 mL sample was plated onto an ampicillin plate and the 
rest was microfuged at 13 000 rpm for 1 minute, resuspended in 100 pL of sterile
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2xTY and plated onto a second ampicillin plate. The plates were then incubated at 
37°C overnight.
Protein Expression
A colony o f SGI 3009 E.coli transformed with wildtype or mutant ai-antitrypsin in a 
PQE31 expression vector was picked from an agar/ampicillin plate and used to 
inoculate 400 mL of 2xTY/40pg ampicillin which was then incubated at 37°C at 250 
rpm overnight. Ten millilitres of this culture was then inoculated into each of 8 litres 
o f 2xTY, 1 OOpg ampicillin/litre, 1 litre/shaker flask. The flasks were incubated at 
37°C/250 rpm, and cell growth monitored by assessing the OD60o of lmL samples 
relative to a 2xTY control. Cell growth was considered to have reached early log 
phase once the ODeoo was between 0.6-0.9, allowing ai-antitrypsin expression to be 
induced in cells without it operating as a negative selection factor. Expression was 
induced by the addition of IPTG to a final concentration of ImM and the temperature 
lowered to 30°C for a further 3 hr. After this the cells were centrifuged down into a 
pellet in 500mL flat-bottomed centrifuge flasks in a Sorval RC 5B Plus centrifuge, 
GS3 rotor at 8 000 rpm for 15 minutes. The pellet was then snap-frozen in liquid 
nitrogen and stored at -70°C until it was required for protein purification as described 
in chapter 3.
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Appendix VI
Polyacrylamide gel electrophoresis (PAGE)
Sodium dodecyl sulphate (SDS-) PAGE
SDS-PAGE stock solutions
Acrylamide 30% (w/v) acrylamide:0.8% (w/v) bis-acrylamide
Separation gel buffer 1.5M Tris/HCl pH 8.8
Stacking gel buffer 0.75M Tris pH 6.5 with H3P 0 4
1 Ox running buffer 0.25M Tris/HCl, 1.92M Glycine pH 8.8
Sample loading buffer lOmL stacking gel buffer, 2mL glycerol, 0.04% (w/v)
bromophenol blue in 20mL of water, 3.0% (w/v) SDS
Stain 0.5% (w/v) Coomassie Blue R250, 45% (v/v) methanol,
10% (v/v) glacial acetic acid in water
Destain 20% (v/v) methanol, 10% glacial acetic acid in water
AMPS 10% ammonium persulphate (w/v) in water
TEMED NNN’N ’-tetramethylethylenediamine
SDS-PAGE Gel mixes
7.5% 10% 15% 20% Stacking gel,
(w/v) (w/v) (w/v) (w/v) 4.5% (w/v)
Buffer 3.75mL 3.75mL 3.75mL 3.75mL 1.6mL
Acrylamide 3.75mL 5mL 7.5mL lOmL 1,6mL
Water 7.3mL 6mL 3.4mL 0.9mL 10.6mL
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10% (w/v) SDS 150pL 150pL 150pL 150pL 150pL
TEMED 20pL 20pL 20pL 20pL 25pL
Sucrose 2.5g 2.5g
10% bromophenol blue 150pL 150pL
10% AMPS Added as descri 5ed in text
SDS-PAGE was carried out in a BioRad Mini Protean II system using a continuous 
buffer method, according to the method of Laemmli (1970). Gradient gels were 
poured with acrylamide gradients using a double chamber gradient forming system. 
The higher percentage acrylamide (w/v) solution was added to the chamber closest to 
the outlet port and the lower percentage acrylamide (w/v) solution to the other 
chamber resulting in a gel with the maximum acrylamide concentration at the bottom. 
The solutions in each chamber (1.75mT) were mixed constantly using a magnetic 
stirrer, 7.5pL of freshly prepared 10% AMPS solution was added to each chamber and 
the tap between the two chambers was opened. The acrylamide solutions were then 
allowed to flow through the tubing attached to the outlet port of the gradient former 
and a 21-gauge butterfly needle into the glass plates.
The gradient was formed by the gradual mixing of the lower concentration acrylamide 
solution into the higher concentration chamber as the solution from this chamber ran 
into the glass plates. In contrast non-gradient gels were poured directly by pipetting 
3.5mL of acrylamide solution of the required concentration thoroughly mixed with 
15pL of freshly prepared 10% AMPS between the glass plates.
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In either case, after pouring, lmL of water was overlaid and the gel left for 30 minutes 
at room temperature to polymerise. Once set firm the water overlaying the separation 
gel was poured off. One and a half millilitres of stacking gel plus 20pL of 10% AMPS 
was then poured over the separation gel and a well forming comb inserted. Once set 
the comb was removed, the wells were washed out with water and the gel placed into 
the running apparatus according to the manufacturers instructions. Running buffer 
was then added to the top and bottom reservoirs to form a continuous system.
Samples were prepared by adding an equal volume of SDS sample buffer and heating 
at 95°C for 2 minutes prior to loading onto the gel. The gel was run at a constant 
voltage o f 150V at room temperature until the bromophenol blue marker reached the 
bottom of the gel. Protein bands were visualised by staining with Coomassie brilliant 
blue and then destained until the background was clear.
Non-denaturing PAGE
Non-denaturing PAGE stock solutions
Acrylamide 30% (w/v) acrylamide:0.8% (w/v) bis-acrylamide
Separation gel buffer 1.5M Tris/HCl pH 8.9
Stacking gel buffer 0.47M Tris pH 6.9 with H3P 0 4
Anode running buffer lOOmM Tris/HCl pH 7.8
Cathode running buffer 53mM Tris/HCl, 68mM Glycine pH 8.2
Sample loading buffer lOmL stacking gel buffer, 2mL glycerol, 0.04% (w/v) 
bromophenol blue in 20mL of water
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Stain 0.5% (w/v) Coomassie Blue R250, 45% (v/v) methanol, 
10% (v/v) glacial acetic acid in water
Destain 20% (v/v) methanol, 10% glacial acetic acid in water
AMPS 10% ammonium persulphate (w/v) in water
TEMED NNN ’N ’ -tetramethylethylenediamine
Gel mixes
7.5% (w/v) 15% (w/v) Stacking gel, 5.4% (w/v)
Buffer 3.75mL 3.75mL 1.6mL
Acrylamide 3.75mL 7.5mL 2.7mL
Water 7.3mL 3.5mL 10.6mL
TEMED 1 lpL l l p L 25pL
Sucrose — 1.5g
10%AMPS Added as described in text
Non-denaturing gels were run in the same BioRad Mini Protean II system as SDS gels 
but using a discontinuous buffer system. Most gels were poured as 7.5-15% (w/v) 
gradients using a double chamber gradient fonning system in the same way as the SDS 
gels were poured. One millilitre stacking gel plus 20pL of 10% AMPS was then 
poured over the separation gel and a well-forming comb inserted. Once set, the comb 
was removed, the wells were washed out with water and the gel was placed into the 
running apparatus according to the manufacturers instructions. Cathodic running 
buffer was placed in the top reservoir and anodic running buffer in the lower reservoir.
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Seven and a half microgram samples were prepared by adding the appropriate volume 
of 5x loading buffer. The samples were then loaded into wells and the gels run at 
150V until the loading buffer dye front reached the bottom. Protein bands were 
visualised by staining with Coomassie brilliant blue and destained until background 
was clear.
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